[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1319
1. Mobley BC, Roulston D, Shah GV, Bijwaard KE, McKeever PE: Peripheral primitive neuroectodermal tumor/Ewing's sarcoma of the craniospinal vault: case reports and review. Hum Pathol; 2006 Jul;37(7):845-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral primitive neuroectodermal tumor/Ewing's sarcoma of the craniospinal vault: case reports and review.
  • The peripheral primitive neuroectodermal tumor/Ewing's sarcoma family tumor (pPNET/ESFT) group includes small round cell tumors of the bone, soft tissue, and nerve with morphological attributes of the germinal neuroepithelium.
  • [MeSH-major] Brain Neoplasms / pathology. Cauda Equina / pathology. Neuroectodermal Tumors, Primitive, Peripheral / pathology. Peripheral Nervous System Neoplasms / pathology. Sarcoma, Ewing / pathology
  • [MeSH-minor] Adult. Antigens, CD / metabolism. Back Pain / etiology. Blotting, Southern. Cell Adhesion Molecules / metabolism. Chromosome Aberrations. Chromosomes, Human, Pair 22 / genetics. Diagnosis, Differential. Headache / etiology. Humans. Male. Meningioma / pathology. Oncogene Proteins, Fusion / genetics. Proto-Oncogene Protein c-fli-1 / genetics. RNA-Binding Protein EWS. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16784984.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / EWS-FLI fusion protein; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Protein c-fli-1; 0 / RNA-Binding Protein EWS
  • [Number-of-references] 68
  •  go-up   go-down


2. Hayes AJ, Neuhaus SJ, Clark MA, Thomas JM: Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma. Ann Surg Oncol; 2007 Jan;14(1):230-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma.
  • BACKGROUND: Isolated limb perfusion (ILP) with melphalan is used in the treatment of advanced in-transit melanoma but has no real efficacy for irresectable soft tissue sarcomas arising in the extremities.
  • The addition of tumor necrosis factor (TNF)-alpha may increase response rates for bulky melanoma and for sarcoma, but the potential for major systemic toxicity has limited its use.
  • RESULTS: Forty-nine ILPs were performed for melanoma (n = 30), sarcoma (n = 16), or other tumors (n = 3).
  • The most common indications were widespread in-transit disease for melanoma (n = 29) and irresectable primary disease for sarcoma (n = 9).
  • Complete and partial responses for melanoma were 40% and 37%, and for sarcoma they were 20% and 33%.
  • At a median follow-up of 14 months, 66% of melanoma patients who responded had not experienced local progression, compared with only 37% of sarcoma patients.
  • Progression-free survival was significantly less for patients with sarcoma than melanoma (P = .0476).
  • Four of 16 patients with sarcoma subsequently required amputation for progressive disease.
  • Significant response rates were also seen in irresectable sarcoma, although the duration of response was limited.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Chemotherapy, Cancer, Regional Perfusion. Melanoma / drug therapy. Melphalan / administration & dosage. Sarcoma / drug therapy. Skin Neoplasms / drug therapy. Tumor Necrosis Factor-alpha / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Extremities. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17066234.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  •  go-up   go-down


3. Bache M, Kappler M, Wichmann H, Rot S, Hahnel A, Greither T, Said HM, Kotzsch M, Würl P, Taubert H, Vordermark D: Elevated tumor and serum levels of the hypoxia-associated protein osteopontin are associated with prognosis for soft tissue sarcoma patients. BMC Cancer; 2010;10:132
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated tumor and serum levels of the hypoxia-associated protein osteopontin are associated with prognosis for soft tissue sarcoma patients.
  • However, only a few studies investigated the prognostic impact of expression of OPN in soft tissue sarcomas (STS) yet.
  • METHODS: This study is based on tumor and serum samples from 93 adult STS patients.
  • We investigated OPN protein levels in serum (n = 86) and tumor tissue (n = 80) by ELISA and OPN mRNA levels in tumor tissue (n = 68) by quantitative real-time PCR.
  • RESULTS: No correlation was found between OPN levels in serum and tumor tissue.
  • OPN protein levels in the tumor tissue were associated with higher stage (p = 0.06), higher grade (p = 0.003), subtype (p = 0.07) and an increased rate of relapse (p = 0.02).
  • In addition, using a Cox's proportional hazards regression model, we found that an elevated OPN protein level in the serum and tumor tissue extracts is a significant negative prognostic factor for patients with STS.
  • CONCLUSION: Our data suggest OPN protein in serum as well as in tumor tissue extracts is an important prognostic factor for soft tissue sarcoma patients.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Osteopontin / metabolism. Sarcoma / metabolism. Soft Tissue Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Hypoxia / physiology. Humans. Middle Aged. Neoplasm Staging. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2007 Dec;14(12):3419-27 [17896150.001]
  • [Cites] Oncogene. 2007 Nov 1;26(50):7170-4 [17525744.001]
  • [Cites] Cell Mol Biol Lett. 2008;13(1):11-9 [17952379.001]
  • [Cites] Cancer Metastasis Rev. 2008 Mar;27(1):103-18 [18049863.001]
  • [Cites] Curr Med Chem. 2008;15(4):322-38 [18288988.001]
  • [Cites] Head Neck. 2008 Jun;30(6):776-81 [18228527.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Aug;134(8):909-17 [18210151.001]
  • [Cites] Lab Invest. 2008 Dec;88(12):1264-77 [18838962.001]
  • [Cites] Anticancer Res. 2008 Nov-Dec;28(6B):4105-10 [19192668.001]
  • [Cites] J Cell Physiol. 2000 Jul;184(1):118-30 [10825241.001]
  • [Cites] Cancer Lett. 2001 Sep 20;170(2):199-205 [11463499.001]
  • [Cites] Virchows Arch. 2001 Nov;439(5):668-74 [11764388.001]
  • [Cites] Biochim Biophys Acta. 2001 Dec 28;1552(2):61-85 [11825687.001]
  • [Cites] Curr Mol Med. 2001 Nov;1(5):621-32 [11899236.001]
  • [Cites] Lancet. 2002 Mar 16;359(9310):943-5 [11918915.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3417-27 [12067984.001]
  • [Cites] Virchows Arch. 2002 Oct;441(4):345-9 [12404059.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1098-104 [12631613.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1588-96 [15014008.001]
  • [Cites] Eur J Cancer. 1993;29A(15):2089-93 [8297645.001]
  • [Cites] Lab Invest. 1995 Jan;72(1):55-63 [7837791.001]
  • [Cites] Int J Cancer. 1998 Oct 23;79(5):502-8 [9761120.001]
  • [Cites] Br J Cancer. 2005 Aug 22;93(4):453-7 [16091764.001]
  • [Cites] Cancer Biol Ther. 2005 Jul;4(7):740-6 [15970685.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):8019-27 [16299231.001]
  • [Cites] Cancer Biol Ther. 2005 Dec;4(12):1336-41 [16258259.001]
  • [Cites] Int J Cancer. 2006 May 1;118(9):2255-61 [16331611.001]
  • [Cites] Oncogene. 2006 Apr 6;25(15):2192-202 [16288209.001]
  • [Cites] BMC Cancer. 2006;6:207 [16911785.001]
  • [Cites] BMC Cancer. 2006;6:237 [17022822.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1481-7 [17056190.001]
  • [Cites] Expert Opin Ther Targets. 2007 Jan;11(1):81-90 [17150036.001]
  • [Cites] Cancer Lett. 2007 Mar 8;247(1):98-102 [16675104.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Feb;292(2):C919-26 [17005603.001]
  • [Cites] Radiother Oncol. 2007 Jun;83(3):389-97 [17499868.001]
  • [Cites] Oncogene. 2007 Sep 27;26(44):6361-71 [17452979.001]
  • [Cites] Int J Cancer. 2008 Feb 15;122(4):889-97 [17960616.001]
  • (PMID = 20377868.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 106441-73-0 / Osteopontin
  • [Other-IDs] NLM/ PMC2856551
  •  go-up   go-down


Advertisement
4. Reichardt P, Nielsen OS, Bauer S, Hartmann JT, Schöffski P, Christensen TB, Pink D, Daugaard S, Marreaud S, Van Glabbeke M, Blay JY, EORTC Soft Tissue and Bone Sarcoma Group: Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer; 2007 Apr;43(6):1017-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma Group.
  • No standard treatment is established for patients with advanced soft tissue sarcoma after previous chemotherapy with anthracyclines and ifosfamide, given either in combination or sequentially.
  • Since some activity against soft tissue sarcomas, especially leiomyosarcomas, has been reported for topoisomerase I-inhibitors, a study with a new and more potent agent seemed justified.
  • We report on a prospective multicentre phase II study of Exatecan in adult soft tissue sarcomas failing 1 or 2 lines of chemotherapy in advanced phase, performed within the STBSG of EORTC.
  • In pretreated soft tissue sarcoma patients, Exatecan is well tolerated but does not achieve any objective responses.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Camptothecin / analogs & derivatives. Leiomyosarcoma / drug therapy. Sarcoma, Synovial / drug therapy
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Hematologic Diseases / chemically induced. Humans. Infusions, Intravenous. Male. Middle Aged. Prospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17336054.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / exatecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


5. Gaumann A, Strubel G, Bode-Lesniewska B, Schmidtmann I, Kriegsmann J, Kirkpatrick CJ: The role of tumor vascularisation in benign and malignant cardiovascular neoplasms: a comparison of cardiac myxoma and sarcomas of the pulmonary artery. Oncol Rep; 2008 Aug;20(2):309-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since the significance of the assessment of angiogenesis in soft tissue tumors is still a matter of debate, we investigated the vascularisation of cardiac myxomas and compared it with pulmonary artery sarcomas (PAS).
  • [MeSH-major] Heart Neoplasms / blood supply. Myxoma / blood supply. Neovascularization, Pathologic / pathology. Sarcoma / blood supply. Vascular Neoplasms / blood supply
  • [MeSH-minor] Adult. Aged. Alkaline Phosphatase / metabolism. Anoxia. Female. Humans. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Immunoenzyme Techniques. Male. Middle Aged. Prognosis. Pulmonary Artery. Receptor, Platelet-Derived Growth Factor alpha / metabolism. Survival Rate. Vascular Endothelial Growth Factor A / metabolism. Vascular Endothelial Growth Factor Receptor-1 / metabolism. Vascular Endothelial Growth Factor Receptor-2 / metabolism

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18636191.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


6. Al-Sobhi EM, Jeha TM, Al-Taher MI: Granulocytic sarcoma causing cord compression in a pregnant woman with acute myeloid leukemia and t(8;21). Saudi Med J; 2008 Nov;29(11):1658-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma causing cord compression in a pregnant woman with acute myeloid leukemia and t(8;21).
  • It may involve any organ system, but mostly it affects the bone and soft tissue of the head and neck.
  • Granulocytic sarcoma resulting in spinal cord compression is rare.
  • [MeSH-major] Chromosomes, Human, Pair 21. Chromosomes, Human, Pair 8. Leukemia, Myeloid, Acute / complications. Pregnancy Complications, Neoplastic / pathology. Sarcoma, Myeloid / pathology. Translocation, Genetic. Umbilical Cord / pathology
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Pregnancy


7. Altan E, Bitik B, Kalpakci Y, Dogan E, Altundag K: Probable hepatotoxicity related to Nerium oleander extract in a patient with metastatic synovial sarcoma of the knee. J Altern Complement Med; 2009 Feb;15(2):113
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Probable hepatotoxicity related to Nerium oleander extract in a patient with metastatic synovial sarcoma of the knee.
  • [MeSH-major] Drug-Induced Liver Injury / etiology. Nerium / adverse effects. Plant Extracts / adverse effects. Sarcoma, Synovial. Soft Tissue Neoplasms
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Fatal Outcome. Female. Humans. Injections, Intramuscular. Knee Joint. Lung Neoplasms / secondary

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19216656.001).
  • [ISSN] 1557-7708
  • [Journal-full-title] Journal of alternative and complementary medicine (New York, N.Y.)
  • [ISO-abbreviation] J Altern Complement Med
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Plant Extracts
  •  go-up   go-down


8. Koontz BF, Clough RW, Halperin EC: Palliative radiation therapy for metastatic Ewing sarcoma. Cancer; 2006 Apr 15;106(8):1790-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative radiation therapy for metastatic Ewing sarcoma.
  • BACKGROUND: Although radiotherapy is an accepted component of curative treatment for Ewing sarcoma (EWS), to the authors' knowledge, there are scant data evaluating its use for palliation.
  • [MeSH-major] Palliative Care. Sarcoma, Ewing / radiotherapy. Sarcoma, Ewing / secondary
  • [MeSH-minor] Adolescent. Adult. Bone Neoplasms / radiotherapy. Bone Neoplasms / secondary. Child. Child, Preschool. Female. Humans. Male. Radiotherapy Dosage. Soft Tissue Neoplasms / radiotherapy. Soft Tissue Neoplasms / secondary. Survival Rate

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 American Cancer Society
  • (PMID = 16534788.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Wada T, Kawai A, Ihara K, Sasaki M, Sonoda T, Imaeda T, Yamashita T: Construct validity of the Enneking score for measuring function in patients with malignant or aggressive benign tumours of the upper limb. J Bone Joint Surg Br; 2007 May;89(5):659-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated the construct validity of the Musculoskeletal Tumour Society rating scale (Enneking score) as a functional measure for patients with sarcoma involving the upper limb.
  • We compared the Enneking score by examining the correlation between two patient-derived outcome measures, the Disability of the Arm, Shoulder, and Hand (DASH) questionnaire and the Medical Outcomes Study Short Form-36 (SF-36) as indicators of functional status in 40 patients with malignant or aggressive benign bone and soft-tissue tumours of the upper limb who had undergone surgical treatment.
  • [MeSH-major] Bone Neoplasms / physiopathology. Sarcoma / physiopathology. Severity of Illness Index. Soft Tissue Neoplasms / physiopathology. Upper Extremity / physiopathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disability Evaluation. Female. Humans. Male. Middle Aged. Pain Measurement / methods. Recovery of Function. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17540754.001).
  • [ISSN] 0301-620X
  • [Journal-full-title] The Journal of bone and joint surgery. British volume
  • [ISO-abbreviation] J Bone Joint Surg Br
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  •  go-up   go-down


10. Kim JS, Lee JS, Yoon JO, Park JB: Reconstruction of the shoulder region using a pedicled latissimus dorsi flap after resection of soft tissue due to sarcoma. J Plast Reconstr Aesthet Surg; 2009 Sep;62(9):1215-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reconstruction of the shoulder region using a pedicled latissimus dorsi flap after resection of soft tissue due to sarcoma.
  • Six patients underwent reconstruction of soft tissue using a pedicled latissimus dorsi flap after tumour resection of the shoulder region.
  • [MeSH-major] Reconstructive Surgical Procedures / methods. Sarcoma / surgery. Shoulder / surgery. Soft Tissue Neoplasms / surgery. Surgical Flaps / blood supply
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Muscle, Skeletal / blood supply. Muscle, Skeletal / transplantation. Patient Satisfaction. Retrospective Studies. Young Adult


11. Dewhirst MW, Poulson JM, Yu D, Sanders L, Lora-Michiels M, Vujaskovic Z, Jones EL, Samulski TV, Powers BE, Brizel DM, Prosnitz LR, Charles HC: Relation between pO2, 31P magnetic resonance spectroscopy parameters and treatment outcome in patients with high-grade soft tissue sarcomas treated with thermoradiotherapy. Int J Radiat Oncol Biol Phys; 2005 Feb 1;61(2):480-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relation between pO2, 31P magnetic resonance spectroscopy parameters and treatment outcome in patients with high-grade soft tissue sarcomas treated with thermoradiotherapy.
  • PURPOSE: In a prior study, the combination of (31)P magnetic resonance spectroscopy (MRS)-based intracellular pH (pHi) and T2 relaxation time was highly predictive of the pathologic complete response (pCR) rate in a small series of patients with soft tissue sarcomas (STSs) treated with thermoradiotherapy.
  • Currently, 50% of all STS patients with high-grade tumors develop distant metastasis even when excellent local control is achieved.
  • [MeSH-major] Hyperthermia, Induced. Sarcoma / secondary. Sarcoma / therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Hydrogen-Ion Concentration. Magnetic Resonance Imaging. Magnetic Resonance Spectroscopy. Male. Middle Aged. Odds Ratio. Oxygen / metabolism. Partial Pressure. Phosphorus Isotopes. Prospective Studies. Radiotherapy Dosage. Survival Analysis


12. Gibbaoui H, Yaman M: Urgent pneumonectomy for metastatic sarcoma. J Thorac Cardiovasc Surg; 2007 Dec;134(6):1599-600
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urgent pneumonectomy for metastatic sarcoma.
  • [MeSH-major] Fibrosarcoma / surgery. Lung Neoplasms / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Pneumonectomy. Radiotherapy, Adjuvant. Thigh / surgery

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18023698.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Kayton ML, Meyers P, Wexler LH, Gerald WL, LaQuaglia MP: Clinical presentation, treatment, and outcome of alveolar soft part sarcoma in children, adolescents, and young adults. J Pediatr Surg; 2006 Jan;41(1):187-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical presentation, treatment, and outcome of alveolar soft part sarcoma in children, adolescents, and young adults.
  • PURPOSE: Alveolar soft part sarcoma is a rare soft tissue neoplasm that can affect children and adolescents.
  • To define the clinical presentation, treatment, and outcome of young people with this rare sarcoma, we reviewed our clinical experience.
  • METHODS: After institutional review board approval, we examined the records of all patients younger than 25 years old who received treatment at our institution for alveolar soft part sarcoma in the past 30 years.
  • CONCLUSIONS: Achievement of complete microscopic resection is critical in localized alveolar soft part sarcoma, but incomplete excision and misdiagnosis are often encountered.
  • [MeSH-major] Sarcoma / pathology. Sarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Age Factors. Child. Disease Progression. Embolization, Therapeutic. Female. Follow-Up Studies. Humans. Male. Neoplasm Metastasis. Retrospective Studies. Survival Analysis. Treatment Outcome


14. Shaariyah MM, Mazita A, Masaany M, Razif MY, Isa MR, Asma A: Synovial sarcoma: a rare presentation of parapharyngeal mass. Chin J Cancer; 2010 Jun;29(6):631-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synovial sarcoma: a rare presentation of parapharyngeal mass.
  • Synovial sarcoma is a rare soft tissue sarcoma of the head and neck region involving the parapharyngeal space.
  • The diagnosis of synovial sarcoma can be very challenging to the pathologists.
  • We present a rare case of parapharyngeal synovial sarcoma in a young female patient who had a two-month history of left cervical intumescent mass at level II.
  • Transcervical excision of the mass was performed and the first case of parapharyngeal sarcoma was identified in our center by fluorescence in situ hybridization (FISH) technique.
  • [MeSH-major] Pharyngeal Neoplasms / diagnosis. Pharyngeal Neoplasms / surgery. Sarcoma, Synovial / diagnosis. Sarcoma, Synovial / surgery
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Combined Modality Therapy. Female. Humans. In Situ Hybridization, Fluorescence. Neoplasm, Residual. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20507738.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


15. Ahmad Z, Qureshi A, Idrees R, Azam M: Epidemiological data of common soft tissue sarcomas as seen in our practice. J Clin Pathol; 2010 Apr;63(4):375-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiological data of common soft tissue sarcomas as seen in our practice.
  • [MeSH-major] Sarcoma / epidemiology. Soft Tissue Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Female. Humans. Male. Middle Aged. Pakistan / epidemiology. Sex Distribution. Young Adult

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20354214.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  •  go-up   go-down


16. Badellino F, Toma S: Treatment of soft tissue sarcoma: a European approach. Surg Oncol Clin N Am; 2008 Jul;17(3):649-72, x
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of soft tissue sarcoma: a European approach.
  • This article discusses the treatment of adult soft tissue sarcoma (excluding gastrointestinal stromal tumor), analyzing the principles underlying treatment and the results of surgery, radiotherapy, and chemotherapy.
  • [MeSH-major] Sarcoma / therapy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18486888.001).
  • [ISSN] 1055-3207
  • [Journal-full-title] Surgical oncology clinics of North America
  • [ISO-abbreviation] Surg. Oncol. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 82
  •  go-up   go-down


17. Bleyer A, Montello M, Budd T, Saxman S: National survival trends of young adults with sarcoma: lack of progress is associated with lack of clinical trial participation. Cancer; 2005 May 1;103(9):1891-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] National survival trends of young adults with sarcoma: lack of progress is associated with lack of clinical trial participation.
  • METHODS: In 38,144 young adults with sarcoma who were diagnosed during 1975-1998 and were followed by the National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results Program, the average annual percent change in 5-year survival was derived as a function of patient age.
  • National sarcoma treatment trial data were obtained on 3242 patients who were entered onto NCI-sponsored trials during 1997-2002. RESULTS:.
  • 1) For patients with bone and soft-tissue sarcomas, except Kaposi sarcoma (KS), the least survival improvement occurred between age 15 years and age 45 years.
  • 2) The lowest participation rate in NCI-sponsored sarcoma treatment trials occurred in patients ages 20-44 years.
  • 3) The age-dependent survival improvement and clinical-trial accrual patterns were correlated directly (soft-tissue sarcomas, P < 0.005; bone sarcomas, P < 0.05; KS, P = 0.06), regardless of whether the accrual profile demonstrated a decline or a peak (KS) during early adulthood.
  • [MeSH-major] Bone Neoplasms / mortality. Mortality / trends. Registries / statistics & numerical data. Sarcoma / mortality. Soft Tissue Neoplasms / mortality
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Child. Child, Preschool. Databases, Factual. Humans. Infant. Infant, Newborn. Middle Aged. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published 2005 by the American Cancer Society.
  • (PMID = 15795902.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA13539; United States / NCI NIH HHS / CA / U10 CA45809
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


18. Luini A, Gatti G, Diaz J, Botteri E, Oliveira E, Cecilio Sahium de Almeida R, Veronesi P, Intra M, Pagani G, Naninato P, Viale G: Angiosarcoma of the breast: the experience of the European Institute of Oncology and a review of the literature. Breast Cancer Res Treat; 2007 Sep;105(1):81-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Europe. Female. Humans. Middle Aged. Retrospective Studies. Risk Factors. Sarcoma / diagnosis. Sarcoma / pathology. Sarcoma / radiotherapy. Soft Tissue Neoplasms / diagnosis. Soft Tissue Neoplasms / pathology. Soft Tissue Neoplasms / radiotherapy. Time Factors

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17115110.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


19. Pailoor J, Iyengar KR, Chan KS, Sumithra S: Follicular dendritic cell sarcoma of inguinal lymph node--a case report. Malays J Pathol; 2008 Dec;30(2):115-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular dendritic cell sarcoma of inguinal lymph node--a case report.
  • They show varied histological features and thus can be mistaken for carcinoma or sarcoma.
  • The tumour cells were negative for epithelial, melanocytic, neural, leucocyte and soft tissue tumour markers.
  • [MeSH-major] Dendritic Cell Sarcoma, Follicular / metabolism. Dendritic Cell Sarcoma, Follicular / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Carcinoma / pathology. Carcinoma / secondary. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Immunophenotyping. Inguinal Canal / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19291921.001).
  • [ISSN] 0126-8635
  • [Journal-full-title] The Malaysian journal of pathology
  • [ISO-abbreviation] Malays J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Malaysia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


20. Ishiguro N, Motoi T, Araki N, Ito H, Moriyama M, Yoshida H: Expression of cardiac ankyrin repeat protein, CARP, in malignant tumors: diagnostic use of CARP protein immunostaining in rhabdomyosarcoma. Hum Pathol; 2008 Nov;39(11):1673-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast, focal immunoreactivity for CARP was only observed in 5 (4%) of 125 non-rhabdomyosarcomas, comprising 2 malignant fibrous histiocytomas, 1 angiosarcoma, 1 epithelioid sarcoma, and 1 squamous cell carcinoma of the lung.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Immunohistochemistry. Infant. Male. Middle Aged. Soft Tissue Neoplasms / metabolism. Soft Tissue Neoplasms / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18656235.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ANKRD1 protein, human; 0 / Biomarkers, Tumor; 0 / Muscle Proteins; 0 / Nuclear Proteins; 0 / Repressor Proteins
  •  go-up   go-down


21. Bray F, Engholm G, Hakulinen T, Gislum M, Tryggvadóttir L, Storm HH, Klint A: Trends in survival of patients diagnosed with cancers of the brain and nervous system, thyroid, eye, bone, and soft tissues in the Nordic countries 1964-2003 followed up until the end of 2006. Acta Oncol; 2010 Jun;49(5):673-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in survival of patients diagnosed with cancers of the brain and nervous system, thyroid, eye, bone, and soft tissues in the Nordic countries 1964-2003 followed up until the end of 2006.
  • BACKGROUND: Diagnoses of cancer of the brain, thyroid, eye, bone, and soft tissues are categorised by heterogeneity in disease frequency, survival, aetiology and prospects for curative therapy.
  • Relative survival from eye cancer increased with time from approximately 60% in 1964-1968 to 80% 1999-2003, while for bone sarcoma, incidence rates remained stable, mortality rates declined, and 5-year survival increased slightly to around 55-65%.
  • Soft tissue sarcoma incidence and survival have been slowly increasing since the 1960s, with little variation in survival (around 65%) for the most recent period.
  • [MeSH-major] Bone Neoplasms / mortality. Brain Neoplasms / mortality. Eye Neoplasms / mortality. Nervous System Neoplasms / mortality. Soft Tissue Neoplasms / mortality. Thyroid Neoplasms / mortality
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Denmark / epidemiology. Female. Finland / epidemiology. Follow-Up Studies. Humans. Iceland / epidemiology. Incidence. Lymphatic Metastasis. Male. Mass Screening. Middle Aged. Mortality / trends. Neoplasm Staging. Norway / epidemiology. Registries. Risk Factors. Survival Analysis. Survival Rate / trends. Sweden / epidemiology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20192877.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


22. Hawkins DS, Bradfield S, Whitlock JA, Krailo M, Franklin J, Blaney SM, Adamson PC, Reaman G: Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer; 2006 Nov;47(6):790-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PROCEDURE: Patients with Ewing sarcoma family of tumors (ESFT), osteosarcoma (OS), soft tissue sarcomas (STS), medulloblastoma (MB)/primitive neuroectodermal tumor (PNET), astrocytoma, or neuroblastoma (NB) recurrent or refractory to conventional therapy, measurable disease, and adequate organ function were treated with topotecan 0.3 mg/m2/day by continuous intravenous infusion for 21 consecutive days, followed by 7 days without therapy prior to response assessment.
  • Objective responses were seen in 2/20 patients with ESFT (both partial responses, 4 and 19 courses), 0/10 OS patients, and 0/12 STS patients.
  • [MeSH-major] Astrocytoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Neuroblastoma / drug therapy. Neuroectodermal Tumors, Primitive / drug therapy. Sarcoma / drug therapy. Topotecan / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Dose-Response Relationship, Drug. Fatigue / chemically induced. Female. Humans. Infusions, Intravenous. Male. Maximum Tolerated Dose. Neutropenia / chemically induced. Recurrence. Survival Rate. Thrombocytopenia / chemically induced. Time Factors. Treatment Outcome


23. Osanai T, Tsuchiya T, Mura N, Ogino T: Shoulder function after extensive total deltoid excision for treatment of soft-tissue sarcoma: a case report. J Shoulder Elbow Surg; 2007 Mar-Apr;16(2):e9-e12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Shoulder function after extensive total deltoid excision for treatment of soft-tissue sarcoma: a case report.

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17055304.001).
  • [ISSN] 1532-6500
  • [Journal-full-title] Journal of shoulder and elbow surgery
  • [ISO-abbreviation] J Shoulder Elbow Surg
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Yanagi T, Kamada T, Tsuji H, Imai R, Serizawa I, Tsujii H: Dose-volume histogram and dose-surface histogram analysis for skin reactions to carbon ion radiotherapy for bone and soft tissue sarcoma. Radiother Oncol; 2010 Apr;95(1):60-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-volume histogram and dose-surface histogram analysis for skin reactions to carbon ion radiotherapy for bone and soft tissue sarcoma.
  • BACKGROUND AND PURPOSE: To evaluate the usefulness of the dose-volume histogram (DVH) and dose-surface histogram (DSH) as clinically relevant and available parameters that helped to identify bone and soft tissue sarcoma patients at risk of developing late skin reactions, including ulceration, when treated with carbon ion radiotherapy.
  • MATERIALS AND METHODS: Thirty-five patients with bone and soft tissue sarcoma treated with carbon ion beams were studied.
  • [MeSH-major] Bone Neoplasms / radiotherapy. Carbon. Heavy Ions / adverse effects. Sarcoma / radiotherapy. Skin / radiation effects
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Radiotherapy Dosage. Relative Biological Effectiveness

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CARBON .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19767117.001).
  • [ISSN] 1879-0887
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 7440-44-0 / Carbon
  •  go-up   go-down


25. Kunos C, Colussi V, Getty P, Kinsella T: Intraoperative electron radiotherapy for extremity sarcomas does not increase acute or late morbidity. Clin Orthop Relat Res; 2006 May;446:247-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intraoperative electron radiotherapy is used to treat surgical sites that potentially harbor occult tumor immediately after limb-sparing surgical resection of extremity soft tissue sarcomas.
  • In a retrospective study, we evaluated whether intraoperative electron radiotherapy increased 90-day and late (> 90 days) wound complication rates by comparing patients who had adult extremity soft tissue sarcomas treated by limb-sparing surgery and preoperative (n = 14) or postoperative (n = 13) external beam radiotherapy.
  • Our findings suggest intraoperative electron radiotherapy during limb-sparing surgery allows radiation dose escalation without increased 90-day or late-wound complication rates when combined with preoperative or postoperative external beam radiotherapy for patients with extremity soft tissue sarcomas.
  • [MeSH-major] Arm. Intraoperative Care / methods. Leg. Morbidity / trends. Sarcoma / radiotherapy. Sarcoma / surgery
  • [MeSH-minor] Adult. Beta Particles / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prospective Studies. Radiotherapy, Adjuvant. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16467624.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Mentzel T, Kutzner H: Reticular and plexiform perineurioma: clinicopathological and immunohistochemical analysis of two cases and review of perineurial neoplasms of skin and soft tissues. Virchows Arch; 2005 Oct;447(4):677-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reticular and plexiform perineurioma: clinicopathological and immunohistochemical analysis of two cases and review of perineurial neoplasms of skin and soft tissues.
  • The morphological spectrum and the differential diagnosis of perineurial neoplasms of skin and soft tissues are discussed.
  • [MeSH-major] Nerve Sheath Neoplasms / pathology. Skin Neoplasms / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Claudin-1. Diagnosis, Differential. Female. Fibroma / pathology. Glucose Transporter Type 1 / metabolism. Humans. Immunohistochemistry. Lipoma / pathology. Membrane Proteins / metabolism. Middle Aged. Mucin-1 / metabolism. S100 Proteins / metabolism. Sarcoma / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ultrastruct Pathol. 1991 Jul-Oct;15(4-5):335-51 [1755098.001]
  • [Cites] Arch Pathol Lab Med. 1984 Jul;108(7):557-60 [6329127.001]
  • [Cites] Adv Clin Path. 2000 Jan;4(1):25-33 [10936896.001]
  • [Cites] Ann Diagn Pathol. 2005 Feb;9(1):16-23 [15692946.001]
  • [Cites] Histopathology. 1989 Jun;14(6):581-92 [2759555.001]
  • [Cites] Am J Surg Pathol. 1998 Nov;22(11):1368-78 [9808129.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1433-42 [9414186.001]
  • [Cites] J Cutan Pathol. 1997 Oct;24(9):575-9 [9404856.001]
  • [Cites] Am J Surg Pathol. 1999 Jun;23(6):636-50 [10366145.001]
  • [Cites] Arch Pathol Lab Med. 1998 Apr;122(4):366-70 [9648907.001]
  • [Cites] Gen Diagn Pathol. 1997 Jul;143(1):75-81 [9269912.001]
  • [Cites] Am J Dermatopathol. 2003 Apr;25(2):171-3; author reply 173-4 [12652204.001]
  • [Cites] Am J Surg Pathol. 1997 Feb;21(2):164-73 [9042282.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1620-6 [12459629.001]
  • [Cites] Am J Surg Pathol. 2001 Apr;25(4):485-93 [11257623.001]
  • [Cites] Histopathology. 1988 Aug;13(2):171-9 [3169685.001]
  • [Cites] Am J Surg Pathol. 2003 Sep;27(9):1183-96 [12960802.001]
  • [Cites] Ann Diagn Pathol. 2003 Apr;7(2):120-3 [12715338.001]
  • [Cites] Am J Clin Pathol. 1995 Jun;103(6):696-704 [7785653.001]
  • [Cites] Neurosurgery. 1998 Dec;43(6):1478-81; discussion 1481-2 [9848865.001]
  • [Cites] J Cutan Pathol. 1993 Feb;20(1):34-9 [8468415.001]
  • [Cites] Pediatr Dev Pathol. 2003 Mar-Apr;6(2):137-41 [12545405.001]
  • [Cites] Virchows Arch. 2003 Aug;443(2):159-63 [12836021.001]
  • [Cites] Cancer. 1978 May;41(5):1823-9 [647630.001]
  • [Cites] Histopathology. 1994 Sep;25(3):261-7 [7821894.001]
  • [Cites] Histopathology. 2000 Oct;37(4):332-9 [11012740.001]
  • [Cites] Pathol Res Pract. 1999;195(11):759-63 [10605696.001]
  • [Cites] Histopathology. 2001 Nov;39(5):498-502 [11737308.001]
  • [Cites] Virchows Arch. 2004 Oct;445(4):347-53 [15322875.001]
  • [Cites] Histopathology. 2002 Mar;40(3):296-9 [11895499.001]
  • [Cites] Am J Surg Pathol. 2005 Jul;29(7):859-65 [15958849.001]
  • [Cites] Am J Surg Pathol. 2005 Jul;29(7):845-58 [15958848.001]
  • [Cites] Cancer Res. 1996 Mar 1;56(5):1164-7 [8640778.001]
  • (PMID = 16133356.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CLDN1 protein, human; 0 / Claudin-1; 0 / Glucose Transporter Type 1; 0 / Membrane Proteins; 0 / Mucin-1; 0 / S100 Proteins
  •  go-up   go-down


27. Benassi MS, Pazzaglia L, Chiechi A, Alberghini M, Conti A, Cattaruzza S, Wassermann B, Picci P, Perris R: NG2 expression predicts the metastasis formation in soft-tissue sarcoma patients. J Orthop Res; 2009 Jan;27(1):135-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NG2 expression predicts the metastasis formation in soft-tissue sarcoma patients.
  • Enhanced expression levels of NG2 proteoglycan in presurgical original lesions of soft-tissue sarcoma (STS) patients defines with 55% probability the immediate (i.e., within 12 months postsurgery) risk in these individuals to develop postsurgical secondary lesions, independently of any other clinical trait.
  • In our cohort of high-grade STS cases, transcription of NG2 also showed a 81-fold amplification in metastatic lesions, when compared to primitive ones, and this gene overexpression was accompanied by an abundant but nonuniform in situ expression of its product.
  • Therefore, minimally invasive assessment of the transcription levels of the NG2 gene represents a parameter capable of predicting the arising of metastatic disease within a definite postsurgery time interval, and affords in adjunct in the definition of life expectance in STS patients.
  • [MeSH-major] Antigens / biosynthesis. Gene Expression Regulation, Neoplastic. Proteoglycans / biosynthesis. Sarcoma / metabolism. Sarcoma / pathology. Soft Tissue Neoplasms / metabolism. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Metastasis. Prognosis. Transcription, Genetic. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18634019.001).
  • [ISSN] 1554-527X
  • [Journal-full-title] Journal of orthopaedic research : official publication of the Orthopaedic Research Society
  • [ISO-abbreviation] J. Orthop. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens; 0 / Proteoglycans; 0 / chondroitin sulfate proteoglycan 4
  •  go-up   go-down


28. Singh RP, Grimer RJ, Bhujel N, Carter SR, Tillman RM, Abudu A: Adult head and neck soft tissue sarcomas: treatment and outcome. Sarcoma; 2008;2008:654987
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult head and neck soft tissue sarcomas: treatment and outcome.
  • We have retrospectively analysed the experience of a musculoskeletal oncological unit in the management of adult head and neck soft tissue sarcomas from 1990 to 2005.
  • Adult head and neck soft tissue sarcomas have a high mortality rate with a high risk of local recurrence and metastatic disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Aug 15;89(4):868-72 [10951351.001]
  • [Cites] Hematol Oncol Clin North Am. 2001 Apr;15(2):377-88, vii [11370499.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Apr;12(2):379-417 [12916461.001]
  • [Cites] World J Surg. 2003 Jul;27(7):875-83 [14509522.001]
  • [Cites] Ann Surg Oncol. 2004 Jun;11(6):619-28 [15172935.001]
  • [Cites] Am J Clin Oncol. 2005 Jun;28(3):259-63 [15923798.001]
  • [Cites] Lancet. 1997 Dec 6;350(9092):1647-54 [9400508.001]
  • [Cites] Laryngoscope. 2006 May;116(5):780-5 [16652087.001]
  • [Cites] Head Neck. 2007 Aug;29(8):731-40 [17274049.001]
  • [Cites] Clin Orthop Relat Res. 1980 Nov-Dec;(153):106-20 [7449206.001]
  • [Cites] Cancer. 1994 Jul 15;74(2):697-702 [8033050.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1994 Sep;120(9):981-6 [8074826.001]
  • [Cites] Br J Cancer. 1993 Jul;68(1):201-7 [8318414.001]
  • [Cites] Head Neck. 2005 Oct;27(10):916-22 [16136585.001]
  • (PMID = 18382622.001).
  • [ISSN] 1357-714X
  • [Journal-full-title] Sarcoma
  • [ISO-abbreviation] Sarcoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2276692
  •  go-up   go-down


29. Tuy BE, Obafemi AA, Beebe KS, Patterson FR: Case report: elevated serum beta human chorionic gonadotropin in a woman with osteosarcoma. Clin Orthop Relat Res; 2008 Apr;466(4):997-1001
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It also is secreted by gestational trophoblastic tumors, gonadal tumors, and even various nongonadal tumors, including bone and soft tissue sarcomas, as a paraneoplastic syndrome.
  • The literature contains one case report of beta human chorionic gonadotropin production from a primary bone sarcoma occurring in a male patient.
  • Although the clinical diagnosis of a sarcoma was never in doubt, we present this case to emphasize a need to exclude pregnancy in women of childbearing age to avoid delay in biopsy and subsequent management.
  • [MeSH-minor] Adult. Amputation. Biopsy, Needle. Diagnosis, Differential. Fatal Outcome. Female. Humans. Pregnancy. Pregnancy Tests. Up-Regulation

  • Genetic Alliance. consumer health - Osteosarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cancer Res Clin Oncol. 2004 Jun;130(6):357-61 [15042358.001]
  • [Cites] Hum Reprod Update. 2006 Nov-Dec;12(6):769-84 [16877746.001]
  • [Cites] Ann Intern Med. 1973 Jan;78(1):39-45 [4734160.001]
  • [Cites] Surg Gynecol Obstet. 1974 May;138(5):747-51 [4362911.001]
  • [Cites] Cancer Res. 1976 Sep;36(9 PT 2):3476-81 [975106.001]
  • [Cites] Cancer. 1976 Oct;38(4):1684-6 [991086.001]
  • [Cites] J Bone Joint Surg Am. 1977 Dec;59(8):1107-11 [591547.001]
  • [Cites] Fertil Steril. 1982 Jun;37(6):773-8 [7115557.001]
  • [Cites] J Bone Joint Surg Am. 1982 Oct;64(8):1121-7 [7130225.001]
  • [Cites] Cancer. 1984 May 15;53(10):2125-8 [6367934.001]
  • [Cites] Cancer. 1985 Dec 1;56(11):2674-82 [2413978.001]
  • [Cites] Arch Pathol Lab Med. 1989 Apr;113(4):416-9 [2468324.001]
  • [Cites] Cancer Res. 1992 Jul 15;52(14):3901-7 [1377600.001]
  • [Cites] J Bone Joint Surg Am. 1996 May;78(5):656-63 [8642021.001]
  • [Cites] Am J Obstet Gynecol. 1972 Jul 15;113(6):751-8 [4673805.001]
  • (PMID = 18288544.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human
  • [Other-IDs] NLM/ PMC2504678
  •  go-up   go-down


30. Miligi L, Costantini AS, Veraldi A, Benvenuti A, WILL, Vineis P: Cancer and pesticides: an overview and some results of the Italian multicenter case-control study on hematolymphopoietic malignancies. Ann N Y Acad Sci; 2006 Sep;1076:366-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epidemiological studies, although sometimes contradictory, have linked phenoxy acid herbicides with non-Hodgkin's lymphoma (NHL) and Soft Tissue Sarcoma (STS); organochlorine insecticides with STS, NHL, and leukemia; organophosphorous compounds with NHL and leukemia; and triazine herbicides with ovarian cancer.
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Humans. Italy. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Pesticides.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17119216.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pesticides
  • [Number-of-references] 29
  •  go-up   go-down


31. Siehl JM, Thiel E, Schmittel A, Hütter G, Deckert PM, Szelényi H, Keilholz U: Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma: results of a phase II study. Cancer; 2005 Aug 1;104(3):611-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma: results of a phase II study.
  • BACKGROUND: The anthracycline/ifosfamide combination is the most effective chemotherapy in soft tissue sarcoma.
  • CONCLUSIONS: The combination of Ifosfamide and L-Dauno was found to be a highly active chemotherapy regimen for first-line treatment of soft tissue sarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy
  • [MeSH-minor] Adult. Aged. Daunorubicin / administration & dosage. Disease Progression. Drug Administration Schedule. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Ifosfamide / administration & dosage. Infusions, Intravenous. Liposomes. Male. Maximum Tolerated Dose. Middle Aged. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 15968689.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Liposomes; 143011-72-7 / Granulocyte Colony-Stimulating Factor; UM20QQM95Y / Ifosfamide; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


32. Pisters PW, Pollock RE, Lewis VO, Yasko AW, Cormier JN, Respondek PM, Feig BW, Hunt KK, Lin PP, Zagars G, Wei C, Ballo MT: Long-term results of prospective trial of surgery alone with selective use of radiation for patients with T1 extremity and trunk soft tissue sarcomas. Ann Surg; 2007 Oct;246(4):675-81; discussion 681-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of prospective trial of surgery alone with selective use of radiation for patients with T1 extremity and trunk soft tissue sarcomas.
  • OBJECTIVE: We conducted a prospective trial to define the local recurrence rates for selected patients with T1 soft tissue sarcomas (STS) treated by surgery alone.
  • SUMMARY BACKGROUND DATA: Retrospective data suggest that some patients with small STS can be safely treated by surgery alone.
  • METHODS: Patients with T1 primary STS were treated with function-preserving surgery and microscopic assessment of surgical margins.
  • Fifty-one patients (58%) had high-grade STS; 60 (68%) had superficial (T1a) disease.
  • In the R0 surgery-alone arm, the cumulative incidence rates of local recurrence at 5 and 10 years were 7.9% and 10.6%, respectively; and the 5- and 10-year sarcoma-specific death rates were 3.2% and 3.2%.
  • CONCLUSION: Selected patients with primary T1 STS of the extremity and trunk can be treated by R0 surgery alone with acceptable local control and excellent long-term survival.
  • [MeSH-major] Extremities / surgery. Sarcoma / surgery. Soft Tissue Neoplasms / surgery. Thoracic Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Clinical Protocols. Dose Fractionation. Female. Follow-Up Studies. Humans. Longitudinal Studies. Lymphatic Metastasis / pathology. Male. Microsurgery. Middle Aged. Neoplasm Recurrence, Local / pathology. Prospective Studies. Radiotherapy, Adjuvant. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17893504.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Baker LH: Medical and pediatric oncology, not adult and pediatric oncology. J Clin Oncol; 2005 Jun 20;23(18):4003-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medical and pediatric oncology, not adult and pediatric oncology.
  • [MeSH-major] Clinical Trials as Topic. Medical Oncology. Pediatrics. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Child. Humans

  • MedlinePlus Health Information. consumer health - Children's Health.
  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2006 Apr 20;24(12):1958-9; author reply 1959-60 [16622276.001]
  • [CommentIn] J Clin Oncol. 2006 Aug 20;24(24):4042-3; author reply 4043-4 [16921066.001]
  • [CommentOn] J Clin Oncol. 2005 Jun 20;23(18):4031-8 [15767644.001]
  • [CommentOn] J Clin Oncol. 2005 Jun 20;23(18):4039-47 [15961757.001]
  • (PMID = 15767649.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  •  go-up   go-down


34. Eilber FC, Brennan MF, Riedel E, Alektiar KM, Antonescu CR, Singer S: Prognostic factors for survival in patients with locally recurrent extremity soft tissue sarcomas. Ann Surg Oncol; 2005 Mar;12(3):228-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for survival in patients with locally recurrent extremity soft tissue sarcomas.
  • BACKGROUND: Factors prognostic for survival in patients with locally recurrent extremity soft tissue sarcomas (STS) are poorly defined, thus making it difficult to identify high-risk patients who may benefit from adjuvant therapy.
  • METHODS: A total of 1421 patients underwent surgical treatment for primary extremity STS at a single institution between 1982 and 2002.
  • CONCLUSIONS: Histological grade, local recurrence size, and local recurrence-free interval are independently predictive of survival in patients with locally recurrent extremity STS.
  • [MeSH-major] Extremities. Neoplasm Recurrence, Local. Sarcoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Lower Extremity / pathology. Lower Extremity / surgery. Male. Middle Aged. Prognosis. Risk Factors. Upper Extremity / pathology. Upper Extremity / surgery

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15827815.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01CA47179
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


35. Dhingra KK, Mandal S, Roy S, Khurana N: Malignant peripheral nerve sheath tumor of the breast: case report. World J Surg Oncol; 2007;5:142
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Malignant peripheral nerve sheath tumor is a rare soft tissue sarcoma of ectomesenchymal origin.
  • It is the malignant counterpart of benign soft tissue tumors like neurofibromas and schwannomas and may often follow them.
  • Common sites include deeper soft tissues, usually in the proximity of a nerve trunk.
  • [MeSH-minor] Adult. Biomarkers, Tumor / metabolism. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans. Vimentin / metabolism

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Orv Hetil. 1998 Jan 18;139(3):137-9 [9467297.001]
  • [Cites] Cancer. 1984 Sep 15;54(6):1049-57 [6432304.001]
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • [Cites] Arch Pathol Lab Med. 1988 Feb;112(2):155-60 [2447857.001]
  • [Cites] J Surg Oncol. 1995 Aug;59(4):273-5 [7630177.001]
  • [Cites] J Med Assoc Thai. 2006 Mar;89(3):377-9 [16696423.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1573-7 [11894862.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):197-203 [9440743.001]
  • [Cites] Breast J. 2003 Jul-Aug;9(4):332 [12846874.001]
  • [Cites] J Gynecol Obstet Biol Reprod (Paris). 1998 Jun;27(4):441-4 [9690165.001]
  • [Cites] Langenbecks Arch Chir. 1995;380(6):350-3 [8559005.001]
  • (PMID = 18154670.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vimentin
  • [Other-IDs] NLM/ PMC2246134
  •  go-up   go-down


36. King JJ, Fayssoux RS, Lackman RD, Ogilvie CM: Early outcomes of soft tissue sarcomas presenting with metastases and treated with chemotherapy. Am J Clin Oncol; 2009 Jun;32(3):308-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early outcomes of soft tissue sarcomas presenting with metastases and treated with chemotherapy.
  • OBJECTIVES: The purpose of this study is to describe outcomes for patients with metastatic soft tissue sarcoma treated with chemotherapy.
  • METHODS: We retrospectively reviewed the records of 383 soft tissue sarcoma patients treated at our institution from 1997 to 2006.
  • Twenty-nine patients (83%) presented with pulmonary metastasis, 6 with bone metastases (17%), 4 with regional node metastases (11%), and 4 with soft tissue metastases (11%).
  • CONCLUSIONS: Soft tissue sarcoma patients presenting with metastatic disease have a low survival rate, but complete eradication of tumor correlated with longer survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bone Neoplasms / secondary. Female. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433963.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


37. Dimov A: [Surgical treatment of sarcomas in the shoulder joint (with the contribution of two cases)]. Khirurgiia (Sofiia); 2007;(3):69-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two cases from the clinical practice are reported both referring to surgical treatment of soft tissue sarcomas in the humeroscapular zone.
  • [MeSH-major] Bone Neoplasms / surgery. Sarcoma / surgery. Shoulder Joint / surgery
  • [MeSH-minor] Adult. Clavicle / surgery. Female. Humans. Humerus / surgery. Male. Middle Aged. Scapula / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18437115.001).
  • [ISSN] 0450-2167
  • [Journal-full-title] Khirurgii︠a︡
  • [ISO-abbreviation] Khirurgiia (Sofiia)
  • [Language] bul
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


38. MacDougall RH, Kerr GR, Duncan W: Incidence of sarcoma in patients treated with fast neutrons. Int J Radiat Oncol Biol Phys; 2006 Nov 1;66(3):842-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of sarcoma in patients treated with fast neutrons.
  • PURPOSE: The aim of this study is to report the incidence of soft tissue sarcoma in a large group of patients treated with fast neutrons.
  • The main outcome measure was the incidence of new soft-tissue sarcomas during long-term follow-up.
  • RESULTS: Three cases of sarcoma, developing within the treatment volume, were observed in a small group of patients treated some years earlier using fast neutrons.
  • [MeSH-major] Fast Neutrons / adverse effects. Neoplasms, Radiation-Induced / epidemiology. Neoplasms, Second Primary / epidemiology. Sarcoma / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / radiotherapy. Female. Fibrosarcoma / radiotherapy. Follow-Up Studies. Head and Neck Neoplasms / radiotherapy. Humans. Incidence. Male. Middle Aged. Randomized Controlled Trials as Topic. Scotland / epidemiology. Thigh

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17011455.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. da Cunha IW, Kowalski LP, Soares FA: Dedifferentiated liposarcoma of the oral cavity with angiosarcomatous dedifferentiation. Virchows Arch; 2005 Apr;446(4):456-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a unique case of a 42-year-old woman with a dedifferentiated liposarcoma of the soft tissue of the oral cavity with angiosarcomatous dedifferentiation.
  • Dedifferentiation in liposarcomas occurs in about 10% of the cases and, when it occurs, the dedifferentiated areas usually resemble high-grade fibrosarcoma or pleomorphic sarcoma.
  • [MeSH-major] Hemangiosarcoma / pathology. Liposarcoma / pathology. Mouth Neoplasms / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Cell Transformation, Neoplastic. Disease-Free Survival. Female. Humans. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Liposarcoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Head Neck. 1992 Jan-Feb;14(1):1-7 [1624288.001]
  • [Cites] J Otolaryngol. 2002 Apr;31(2):125-8 [12019743.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Sep;94(3):333-7 [12324789.001]
  • [Cites] Int J Surg Pathol. 2002 Jan;10(1):75-9 [11927975.001]
  • [Cites] Am J Surg Pathol. 1998 Aug;22(8):945-55 [9706974.001]
  • [Cites] Semin Diagn Pathol. 2001 Nov;18(4):263-6 [11757866.001]
  • [Cites] Mod Pathol. 2002 Oct;15(10):1020-31 [12379747.001]
  • [Cites] Am J Surg Pathol. 1997 Mar;21(3):271-81 [9060596.001]
  • [Cites] Virchows Arch Pathol Anat Physiol Klin Med. 1962;335:367-88 [13890373.001]
  • [Cites] J Clin Periodontol. 2001 Feb;28(2):109-12 [11168734.001]
  • [Cites] Am J Surg Pathol. 1994 Nov;18(11):1150-7 [7943536.001]
  • [Cites] Ann Surg. 1944 Jan;119(1):86-107 [17858339.001]
  • [Cites] Cancer. 1960 Sep-Oct;13:932-50 [13696965.001]
  • [Cites] Ann Diagn Pathol. 2000 Aug;4(4):252-66 [10982304.001]
  • [Cites] J Oral Pathol Med. 1999 Feb;28(2):92-5 [9950257.001]
  • [Cites] Br J Cancer. 1970 Dec;24(4):696-704 [5503596.001]
  • [Cites] Semin Oncol. 1981 Jun;8(2):185-9 [7196088.001]
  • [Cites] Ann Diagn Pathol. 2002 Apr;6(2):83-93 [12004355.001]
  • [Cites] Acta Pathol Jpn. 1982 Nov;32(6):933-48 [6297235.001]
  • [Cites] Am J Surg Pathol. 1994 Dec;18(12):1213-23 [7977944.001]
  • [Cites] Cancer. 1995 Sep 15;76(6):1051-8 [8625207.001]
  • [Cites] Oral Oncol. 2002 Dec;38(8):757-62 [12570054.001]
  • [Cites] Pathol Int. 2000 Jul;50(7):558-61 [10886740.001]
  • (PMID = 15806379.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 25
  •  go-up   go-down


40. Berger F, Winkler EC, Ruderer C, Reiser MF: [Imaging of soft tissue sarcomas: standard approaches and new strategies]. Chirurg; 2009 Mar;80(3):175-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Imaging of soft tissue sarcomas: standard approaches and new strategies].
  • Soft tissue sarcomas are rare malignant neoplasms accounting for only 1% of malignant tumors in adults.
  • [MeSH-major] Diagnostic Imaging. Sarcoma / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease Progression. Disease-Free Survival. Extremities / pathology. Extremities / surgery. Follow-Up Studies. Humans. Neoplasm Invasiveness / pathology. Neoplasm Staging. Neoplasms, Radiation-Induced / diagnosis. Neoplasms, Radiation-Induced / drug therapy. Neoplasms, Radiation-Induced / pathology. Neoplasms, Radiation-Induced / surgery. Neovascularization, Pathologic / diagnosis. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / pathology. Neovascularization, Pathologic / surgery. Prognosis. Radiotherapy, Adjuvant. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Expert Rev Anticancer Ther. 2006 Aug;6(8):1251-60 [16925491.001]
  • [Cites] Eur Radiol. 2005 Dec;15(12):2448-56 [16132930.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Cancer Imaging. 2008 Oct 04;8 Spec No A:S61-8 [18852082.001]
  • [Cites] Nat Rev Drug Discov. 2007 Sep;6(9):734-45 [17690708.001]
  • [Cites] AJR Am J Roentgenol. 1988 Mar;150(3):615-20 [3257620.001]
  • [Cites] Curr Opin Oncol. 2006 Jul;18(4):369-73 [16721133.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1052-6 [11287975.001]
  • [Cites] Arch Surg. 1999 Feb;134(2):190-4 [10025462.001]
  • [Cites] Clin Orthop Relat Res. 2008 Sep;466(9):2071-80 [18516656.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1679-89 [8622088.001]
  • [Cites] Radiology. 1995 Dec;197(3):831-9 [7480764.001]
  • [Cites] Ther Clin Risk Manag. 2007 Jun;3(2):341-8 [18360643.001]
  • [Cites] Ann Oncol. 2005 Jul;16(7):1054-60 [15917312.001]
  • [Cites] J Bone Joint Surg Am. 1996 May;78(5):650-5 [8642020.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):355-65 [9742918.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1652-9 [8156492.001]
  • [Cites] Eur J Cancer. 2003 Jul;39(11):1568-76 [12855264.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2832-9 [9256126.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17 ):6171-6 [16144917.001]
  • [Cites] Cancer Imaging. 2008 Mar 25;8:81-6 [18390391.001]
  • [Cites] Ann Surg. 1987 May;205(5):473-81 [3579397.001]
  • [Cites] World J Gastroenterol. 2006 Feb 7;12(5):703-8 [16521182.001]
  • [Cites] Cancer. 2005 Aug 15;104(4):669-75 [16003776.001]
  • [Cites] Abdom Imaging. 2006 Mar-Apr;31(2):188-93 [16447089.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(14 ):2012-20 [12957455.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Jun;19(3):471-87, vi [15939192.001]
  • [Cites] Radiol Clin North Am. 1993 Mar;31(2):359-72 [8446754.001]
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1753-9 [17470865.001]
  • [Cites] AJR Am J Roentgenol. 2004 Dec;183(6):1619-28 [15547201.001]
  • [Cites] Ann Surg. 1982 Sep;196(3):305-15 [7114936.001]
  • [Cites] Int J Hyperthermia. 2002 Nov-Dec;18(6):486-9 [12537749.001]
  • (PMID = 19224185.001).
  • [ISSN] 1433-0385
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 39
  •  go-up   go-down


41. Kilvaer TK, Valkov A, Sorbye S, Smeland E, Bremnes RM, Busund LT, Donnem T: Profiling of VEGFs and VEGFRs as prognostic factors in soft tissue sarcoma: VEGFR-3 is an independent predictor of poor prognosis. PLoS One; 2010;5(12):e15368
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Profiling of VEGFs and VEGFRs as prognostic factors in soft tissue sarcoma: VEGFR-3 is an independent predictor of poor prognosis.
  • BACKGROUND: In non-gastrointestinal stromal tumor soft tissue sarcoma (non-GIST STS) optimal treatment is surgery with wide resection margins.
  • This study investigates the prognostic impact of VEGFs and VEGFRs in non-GIST STS with wide and non-wide resection margins.
  • METHODS: Tumor samples from 249 patients with non-GIST STS were obtained and tissue microarrays were constructed for each specimen.
  • [MeSH-major] Gene Expression Profiling. Receptors, Vascular Endothelial Growth Factor / metabolism. Sarcoma / metabolism. Soft Tissue Neoplasms / metabolism. Vascular Endothelial Growth Factor A / metabolism
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Lymphangiogenesis. Male. Middle Aged. Neovascularization, Pathologic. Prognosis. Vascular Endothelial Growth Factor Receptor-3 / metabolism

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2004 Feb;91(2):242-7 [14760675.001]
  • [Cites] Br J Cancer. 2001 Jun 15;84(12):1610-5 [11401313.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):806-13 [15510161.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3566-70 [7724599.001]
  • [Cites] N Engl J Med. 1995 Dec 28;333(26):1757-63 [7491141.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):350-62 [8996162.001]
  • [Cites] J Cancer Res Clin Oncol. 1999 Oct;125(10):577-81 [10473871.001]
  • [Cites] Cardiovasc Res. 2005 Feb 15;65(3):550-63 [15664381.001]
  • [Cites] ANZ J Surg. 2006 Mar;76(3):104-9 [16626341.001]
  • [Cites] Cancer Metastasis Rev. 2006 Jun;25(2):221-32 [16770534.001]
  • [Cites] Histopathology. 2006 Jul;49(1):87-8 [16842251.001]
  • [Cites] Cancer. 2007 Mar 1;109(5):813-9 [17265525.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Jun;8(6):464-78 [17522591.001]
  • [Cites] J Exp Med. 2007 Jun 11;204(6):1431-40 [17535974.001]
  • [Cites] Ann N Y Acad Sci. 2008;1131:225-34 [18519975.001]
  • [Cites] Nature. 2008 Jul 31;454(7204):656-60 [18594512.001]
  • [Cites] Ann Surg Oncol. 2001 Apr;8(3):260-7 [11314944.001]
  • [Cites] Oncologist. 2008 Nov;13(11):1193-200 [18987047.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Clin Cancer Res. 2009 Aug 15;15(16):5191-8 [19671876.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2009 Nov;21(9):695-705 [19734027.001]
  • [Cites] Eur J Cancer. 2010 Jan;46(1):6-8 [19926474.001]
  • [Cites] Cancer. 2010 Mar 1;116(5):1177-83 [20052715.001]
  • [Cites] Ann Surg Oncol. 2007 Oct;14(10):2876-86 [17647063.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6649-57 [18006765.001]
  • [Cites] J Surg Oncol. 2008 Jan 1;97(1):74-81 [18041747.001]
  • [Cites] Ann Oncol. 2004 Aug;15(8):1261-6 [15277268.001]
  • (PMID = 21179485.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-3
  • [Other-IDs] NLM/ PMC3001883
  •  go-up   go-down


42. Potter BK, Adams SC, Qadir R, Pitcher JD, Temple HT: Fungating soft-tissue sarcomas. Treatment implications and prognostic importance of malignant ulceration. J Bone Joint Surg Am; 2009 Mar 1;91(3):567-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fungating soft-tissue sarcomas. Treatment implications and prognostic importance of malignant ulceration.
  • BACKGROUND: Several variables have been reported as being prognostic with regard to the outcomes of soft-tissue sarcomas.
  • Although the tumors are subjectively ominous, no prior study has been performed to evaluate the treatment or prognosis of fungating soft-tissue sarcomas.
  • METHODS: We performed a retrospective review of all soft-tissue sarcomas treated at our institution between 1989 and 2004 that had been followed for a minimum of two years or until the death of the patient.
  • CONCLUSIONS: Malignant tumor ulceration is an independent predictor of a poor prognosis for patients with a high-grade soft-tissue sarcoma.
  • [MeSH-major] Sarcoma / pathology. Sarcoma / surgery. Ulcer / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19255216.001).
  • [ISSN] 1535-1386
  • [Journal-full-title] The Journal of bone and joint surgery. American volume
  • [ISO-abbreviation] J Bone Joint Surg Am
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Möller E, Stenman G, Mandahl N, Hamberg H, Mölne L, van den Oord JJ, Brosjö O, Mertens F, Panagopoulos I: POU5F1, encoding a key regulator of stem cell pluripotency, is fused to EWSR1 in hidradenoma of the skin and mucoepidermoid carcinoma of the salivary glands. J Pathol; 2008 May;215(1):78-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The EWSR1 gene is known to play a crucial role in the development of a number of different bone and soft tissue tumours, notably Ewing's sarcoma.
  • [MeSH-minor] Adult. Chromosome Mapping. Chromosomes, Human, Pair 22. Chromosomes, Human, Pair 6. Female. Humans. In Situ Hybridization, Fluorescence. Middle Aged. Oncogene Proteins, Fusion / analysis. Oncogene Proteins, Fusion / genetics. Pregnancy. Reverse Transcriptase Polymerase Chain Reaction. Transfection / methods. Translocation, Genetic

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18338330.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Calmodulin-Binding Proteins; 0 / EWSR1 protein, human; 0 / Octamer Transcription Factor-3; 0 / Oncogene Proteins, Fusion; 0 / POU5F1 protein, human; 0 / RNA-Binding Proteins
  •  go-up   go-down


44. Sung KS, Seo SW, Shon MS: The diagnostic value of needle biopsy for musculoskeletal lesions. Int Orthop; 2009 Dec;33(6):1701-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were 142 soft tissue and 167 bony lesions.
  • Overall diagnostic yield was 90.6% for all 309 lesions (bone 91.6% vs. soft tissue 89.3%, p = 0.5125).
  • The diagnostic accuracy of the 185 core needle biopsies, which were confirmed by definitive surgical biopsies, was 84.3% (bone 88.9% vs. soft tissue 79.1%, p = 0.0669).
  • However, for soft tissue tumours, homogenous tumours had a significantly higher diagnostic yield than heterogenous tumours (97.5% vs. 81.4%, p = 0.0036).
  • Diagnostic accuracy for homogenous tumours was also significantly higher than that for heterogenous soft tissue tumours (94.4% vs. 60.6%, p < 0.0001).
  • The image-guided percutaneous needle biopsy of musculoskeletal lesions is a safe and effective procedure if it is performed selectively in soft tissue tumours with homogenous architectures.
  • [MeSH-major] Biopsy, Needle / methods. Bone Neoplasms / diagnosis. Musculoskeletal Diseases / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Diagnosis, Computer-Assisted. Diagnosis, Differential. Female. Hemangioma / diagnosis. Hemangioma / pathology. Humans. Image Processing, Computer-Assisted. Male. Middle Aged. Neurilemmoma / diagnosis. Neurilemmoma / pathology. Retrospective Studies. Sarcoma, Synovial / diagnosis. Sarcoma, Synovial / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Br. 2000 Jan;82(1):50-4 [10697314.001]
  • [Cites] Radiology. 2008 Sep;248(3):962-70 [18710986.001]
  • [Cites] Cancer. 2000 Dec 15;89(12):2677-86 [11135231.001]
  • [Cites] J Ultrasound Med. 2000 Dec;19(12):849-55 [11127010.001]
  • [Cites] Am J Clin Pathol. 2001 Jan;115(1):59-68 [11190808.001]
  • [Cites] J Ultrasound Med. 2002 Mar;21(3):275-81 [11883538.001]
  • [Cites] Radiology. 2002 Jun;223(3):731-7 [12034942.001]
  • [Cites] Isr Med Assoc J. 2003 Jan;5(1):28-30 [12592954.001]
  • [Cites] J Radiol. 2003 Jun;84(6):693-7 [12910175.001]
  • [Cites] Radiology. 1983 Dec;149(3):675-9 [6580673.001]
  • [Cites] Acta Cytol. 1987 Mar-Apr;31(2):177-84 [3469851.001]
  • [Cites] AJR Am J Roentgenol. 1992 Apr;158(4):809-12 [1546597.001]
  • [Cites] J Bone Joint Surg Br. 1991 May;73(3):498-500 [1670457.001]
  • [Cites] AJR Am J Roentgenol. 1996 Jan;166(1):137-41 [8571862.001]
  • [Cites] J Bone Joint Surg Am. 1996 May;78(5):644-9 [8642019.001]
  • [Cites] J Bone Joint Surg Am. 1996 May;78(5):656-63 [8642021.001]
  • [Cites] AJR Am J Roentgenol. 1998 Sep;171(3):759-62 [9725312.001]
  • [Cites] Can Assoc Radiol J. 1999 Apr;50(2):121-5 [10226638.001]
  • [Cites] Am J Clin Pathol. 1999 May;111(5):594-8 [10230349.001]
  • [Cites] Radiology. 1999 Sep;212(3):682-6 [10478232.001]
  • [Cites] ANZ J Surg. 2005 Apr;75(4):187-91 [15839962.001]
  • [Cites] J Surg Oncol. 2006 Jul 1;94(1):21-7 [16788939.001]
  • [Cites] Int Orthop. 2006 Dec;30(6):484-9 [17013643.001]
  • [Cites] Rev Med Chil. 2006 Oct;134(10):1283-7 [17186098.001]
  • [Cites] Skeletal Radiol. 2007 Mar;36(3):181-2 [17139502.001]
  • [Cites] J Ultrasound Med. 2000 Jul;19(7):465-71 [10898300.001]
  • (PMID = 19655141.001).
  • [ISSN] 1432-5195
  • [Journal-full-title] International orthopaedics
  • [ISO-abbreviation] Int Orthop
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2899198
  •  go-up   go-down


45. Lee S, Lee MR, Lee SJ, Ahn HK, Yi J, Yi SY, Seo SW, Sung KS, Park JO, Lee J: Extraosseous osteosarcoma: single institutional experience in Korea. Asia Pac J Clin Oncol; 2010 Jun;6(2):126-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: Extraosseous osteosarcoma (EOO) is a rare soft tissue form of osteosarcoma without involvement of the skeletal system.
  • CONCLUSION: EOO should be treated as a soft tissue sarcoma with aggressive behavior and multimodality treatment should be actively sought to improve treatment outcome.
  • [MeSH-major] Osteosarcoma / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Bone Neoplasms / pathology. Bone Neoplasms / therapy. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Korea. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Osteosarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20565425.001).
  • [ISSN] 1743-7563
  • [Journal-full-title] Asia-Pacific journal of clinical oncology
  • [ISO-abbreviation] Asia Pac J Clin Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


46. Chowdhry M, Hughes C, Grimer RJ, Sumathi V, Wilson S, Jeys L: Bone sarcomas arising in patients with neurofibromatosis type 1. J Bone Joint Surg Br; 2009 Sep;91(9):1223-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two patients subsequently developed a second bone sarcoma, one of which was radiation induced.
  • Four of the primary tumours were osteosarcomas, four were spindle-cell sarcomas and one a Ewing's sarcoma.
  • This study suggests a possible relationship between neurofibromatosis type 1 and the development of a bone sarcoma, the increased risk being estimated at eight times that of the normal population.
  • [MeSH-major] Bone Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Neurofibromatosis 1 / pathology. Osteosarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Dose-Response Relationship, Radiation. Female. Humans. Incidence. Male. Middle Aged. Neoplasms, Radiation-Induced / pathology. Neoplasms, Radiation-Induced / therapy. Retrospective Studies. Young Adult


47. Ng VY, Thomas K, Crist M, Wakely PE Jr, Mayerson J: Fine needle aspiration for clinical triage of extremity soft tissue masses. Clin Orthop Relat Res; 2010 Apr;468(4):1120-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration for clinical triage of extremity soft tissue masses.
  • BACKGROUND: Fine needle aspiration cytology (FNAC) is a rapid and low-morbid alternative to open biopsy or needle core biopsy for soft tissue masses.
  • METHODS: We retrospectively examined the diagnostic accuracy and clinical effectiveness of office-based FNAC performed by a trained pathologist on 213 females and 219 males (mean age, 51.8 years) who presented with a palpable soft tissue mass to one musculoskeletal oncology clinic between 2002 and 2008.
  • Final tissue confirmation by open biopsy or resection was available for 52.2% of benign FNAC and 78.3% of malignant FNAC.
  • [MeSH-major] Biopsy, Fine-Needle. Extremities / pathology. Sarcoma / pathology. Soft Tissue Neoplasms / pathology. Triage / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Reproducibility of Results. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Cytol. 2000 May-Jun;44(3):337-43 [10833988.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Am J Clin Pathol. 2001 Jan;115(1):59-68 [11190808.001]
  • [Cites] Diagn Cytopathol. 2001 May;24(5):307-16 [11335959.001]
  • [Cites] Acta Orthop Scand. 2001 Apr;72(2):150-9 [11372946.001]
  • [Cites] Cancer Control. 2001 May-Jun;8(3):232-8 [11378649.001]
  • [Cites] Acta Orthop Scand Suppl. 2001 Feb;72(300):1-31 [11381580.001]
  • [Cites] Diagn Cytopathol. 2002 Apr;26(4):232-42 [11933269.001]
  • [Cites] Cancer. 2002 Apr 25;96(2):83-91 [11954025.001]
  • [Cites] Diagn Cytopathol. 2002 Jul;27(1):1-4 [12112806.001]
  • [Cites] Diagn Cytopathol. 2002 Dec;27(6):354-61 [12451566.001]
  • [Cites] Cytopathology. 2003 Aug;14(4):173-82 [12873307.001]
  • [Cites] Adv Anat Pathol. 2004 Jan;11(1):24-37 [14676638.001]
  • [Cites] Cytopathology. 2004 Feb;15(1):32-7 [14748789.001]
  • [Cites] Arch Pathol Lab Med. 2004 Jul;128(7):759-64 [15214827.001]
  • [Cites] Acta Orthop Scand. 1985 Oct;56(5):407-12 [4072661.001]
  • [Cites] Arch Pathol Lab Med. 1986 May;110(5):420-4 [3754426.001]
  • [Cites] Acta Cytol. 1986 Nov-Dec;30(6):671-8 [3466503.001]
  • [Cites] J Surg Oncol. 1988 Mar;37(3):168-70 [3352270.001]
  • [Cites] Hum Pathol. 1990 Jun;21(6):669-77 [2190911.001]
  • [Cites] Surgery. 1992 Sep;112(3):536-43 [1519170.001]
  • [Cites] Acta Cytol. 1994 May-Jun;38(3):381-4 [8191828.001]
  • [Cites] Cytopathology. 1995 Aug;6(4):236-47 [8520003.001]
  • [Cites] J Bone Joint Surg Am. 1996 May;78(5):639-43 [8642018.001]
  • [Cites] J Bone Joint Surg Am. 1996 May;78(5):644-9 [8642019.001]
  • [Cites] J Bone Joint Surg Am. 1996 May;78(5):656-63 [8642021.001]
  • [Cites] Am J Surg. 1997 Dec;174(6):694-6; discussion 697-8 [9409599.001]
  • [Cites] Cytopathology. 1998 Oct;9(5):320-8 [9800130.001]
  • [Cites] Virchows Arch. 1999 Mar;434(3):187-91 [10190296.001]
  • [Cites] Am J Clin Pathol. 1999 May;111(5):632-40 [10230353.001]
  • [Cites] Am J Clin Pathol. 2005 Mar;123(3):388-93 [15716235.001]
  • [Cites] Ann Diagn Pathol. 2005 Aug;9(4):197-201 [16084452.001]
  • [Cites] Cancer. 2005 Aug 25;105(4):229-39 [15918176.001]
  • [Cites] N Engl J Med. 2005 Aug 18;353(7):701-11 [16107623.001]
  • [Cites] Mod Pathol. 2006 Jun;19(6):815-9 [16557276.001]
  • [Cites] Clin Orthop Relat Res. 2006 Sep;450:95-100 [16906075.001]
  • [Cites] Diagn Cytopathol. 2007 Dec;35(12):768-73 [18008345.001]
  • [Cites] Cancer. 2007 Dec 25;111(6):491-8 [17941014.001]
  • [Cites] Cancer. 2000 Oct 25;90(5):292-8 [11038426.001]
  • (PMID = 19763717.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2835602
  •  go-up   go-down


48. Tormo V, Andreu FJ: Primary breast synovial sarcoma: a rare primary breast neoplasm. Clin Transl Oncol; 2009 Dec;11(12):854-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary breast synovial sarcoma: a rare primary breast neoplasm.
  • A primary synovial sarcoma based on the breast is rare.
  • Synovial sarcomas account for about 6-9% of soft tissue sarcomas and most commonly develop in the extremity of young adults (80%).
  • We were surprised when the pathologist identified a synovial sarcoma in the histopathology study.
  • [MeSH-major] Breast Neoplasms / diagnosis. Sarcoma, Synovial / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Incidence

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4040-50 [15364967.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2161-9 [8397060.001]
  • [Cites] CA Cancer J Clin. 2004 Mar-Apr;54(2):94-109 [15061599.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):627-34 [15274077.001]
  • [Cites] J Pathol. 1999 Mar;187(4):490-6 [10398111.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):525-34 [11208847.001]
  • (PMID = 20045794.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


49. Arnold PM, Roh S, Ha TM, Anderson KK: Metastatic synovial sarcoma with cervical spinal cord compression treated with posterior ventral resection: case report. J Spinal Cord Med; 2010;33(1):80-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic synovial sarcoma with cervical spinal cord compression treated with posterior ventral resection: case report.
  • CONTEXT: Synovial sarcomas, which represent 5% to 10% of all adult soft-tissue sarcomas, usually metastasize to the lungs.
  • Spinal cord compression due to spinal metastasis occurs in approximately 3% of patients with extraspinal soft-tissue sarcomas.
  • FINDINGS: A 26-year-old woman presented with neck pain, arm weakness, and a history of metastatic synovial sarcoma originating at the right knee.
  • CONCLUSION AND CLINICAL RELEVANCE: Metastatic spinal cord compression from synovial sarcoma is rare.
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Sarcoma, Synovial / pathology. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Orthop Relat Res. 2000 May;(374):247-58 [10818984.001]
  • [Cites] J Bone Joint Surg Br. 2008 Aug;90(8):1090-6 [18669969.001]
  • [Cites] AJR Am J Roentgenol. 2002 Sep;179(3):797-801 [12185067.001]
  • [Cites] Laryngorhinootologie. 2004 Feb;83(2):96-101 [14999584.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1468-73 [15050325.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):627-34 [15274077.001]
  • [Cites] Clin Nucl Med. 1985 Apr;10(4):260-3 [2986892.001]
  • [Cites] Am J Surg Pathol. 1993 Jan;17(1):35-44 [8383468.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1201-8 [8648375.001]
  • [Cites] Auris Nasus Larynx. 1999 Jan;26(1):91-4 [10077262.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Oct;26(9):2402-5 [16219854.001]
  • [Cites] J Neurosurg Spine. 2006 Feb;4(2):179-82 [16506487.001]
  • [Cites] Neurosurgery. 2006 Dec;59(6):E1339; discussion E1339 [17277671.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):105-13 [17592298.001]
  • [Cites] J Surg Oncol. 2008 Mar 15;97(4):314-20 [18286474.001]
  • [Cites] Neurosurgery. 2001 Dec;49(6):1277-86; discussion 1286-7 [11846926.001]
  • (PMID = 20397449.001).
  • [ISSN] 1079-0268
  • [Journal-full-title] The journal of spinal cord medicine
  • [ISO-abbreviation] J Spinal Cord Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2853335
  •  go-up   go-down


50. Jin Y, Shima Y, Furu M, Aoyama T, Nakamata T, Nakayama T, Nakamura T, Toguchida J: Absence of oncogenic mutations of RAS family genes in soft tissue sarcomas of 100 Japanese patients. Anticancer Res; 2010 Jan;30(1):245-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of oncogenic mutations of RAS family genes in soft tissue sarcomas of 100 Japanese patients.
  • MATERIALS AND METHODS: Mutation analyses of three RAS genes (KRAS, HRAS and NRAS) were performed using polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) analyses and PCR direct sequencing in one hundred cases of soft tissue sarcoma (STS) as well as six STS cell lines from Japanese patients.
  • CONCLUSION: Activating mutations of the RAS gene family are uncommon events in soft tissue sarcomas in Japanese patients.
  • [MeSH-major] Genes, ras. Sarcoma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Child. DNA Mutational Analysis. Female. Humans. Japan. Male. Middle Aged. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. Young Adult

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20150643.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


51. Saithna A, Pynsent PB, Grimer RJ: Retrospective analysis of the impact of symptom duration on prognosis in soft tissue sarcoma. Int Orthop; 2008 Jun;32(3):381-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis of the impact of symptom duration on prognosis in soft tissue sarcoma.
  • The objective was to assess whether time to diagnosis is influenced by patient/tumour-related factors and whether or not duration of symptoms has any impact on survival in soft tissue sarcoma.
  • Patient and tumour-related factors significantly associated with longer symptom duration were low-grade, subcutaneous tumours, and epithelioid or synovial sarcoma.
  • [MeSH-major] Sarcoma / diagnosis. Sarcoma / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Infant. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. Proportional Hazards Models. Retrospective Studies. Risk Factors. Time Factors

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4344-52 [12409334.001]
  • [Cites] Eur J Surg Oncol. 2003 Jun;29(5):440-5 [12798748.001]
  • [Cites] Eur J Cancer Clin Oncol. 1988 Oct;24(10):1583-8 [3208802.001]
  • [Cites] BMJ. 2005 Sep 17;331(7517):590 [16166112.001]
  • [Cites] Ann R Coll Surg Engl. 2005 May;87(3):171-3 [15901376.001]
  • [Cites] Br J Cancer. 2005 Jun 6;92(11):1959-70 [15870714.001]
  • [Cites] Eur J Surg Oncol. 2005 May;31(4):443-8 [15837054.001]
  • (PMID = 17377790.001).
  • [ISSN] 0341-2695
  • [Journal-full-title] International orthopaedics
  • [ISO-abbreviation] Int Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2323426
  •  go-up   go-down


52. Bilici A, Ustaalioglu BB, Seker M, Kayahan S: Case report: soft tissue metastasis from immature teratoma of the testis: second case report and review of the literature. Clin Orthop Relat Res; 2010 Sep;468(9):2541-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: soft tissue metastasis from immature teratoma of the testis: second case report and review of the literature.
  • Spread to soft tissue, however, is rare with only four cases with seminoma reported.
  • However, one case with metastasis of testicular immature teratoma to soft tissue was documented previously.
  • CASE DESCRIPTION: We report the case of a 38-year-old man with recurrent immature teratoma of the testis who presented with a painless soft tissue mass in the left thigh previously treated with standard chemotherapy.
  • After removal of the soft tissue mass, his serum alpha-fetoprotein level had returned to the normal range.
  • LITERATURE REVIEW: To our knowledge, this is the second case of immature teratoma of the testis metastasized to soft tissue.
  • PURPOSES AND CLINICAL RELEVANCE: We suggest that for a man with testicular cancer who has a soft tissue mass, metastasis of soft tissue from testicular cancer and other solid malignancies should be considered in the differential diagnosis of a soft tissue mass together with primary soft tissue sarcoma.
  • [MeSH-major] Soft Tissue Neoplasms / secondary. Teratoma / secondary. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Brain Neoplasms / therapy. Chorionic Gonadotropin, beta Subunit, Human / blood. Cranial Irradiation. Humans. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Magnetic Resonance Imaging. Male. Orchiectomy. Thigh. Treatment Outcome. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Skeletal Radiol. 2000 May;29(5):270-4 [10883446.001]
  • [Cites] Br J Radiol. 2008 Jul;81(967):e188-90 [18559897.001]
  • [Cites] AJR Am J Roentgenol. 2002 Dec;179(6):1644; author reply 1644 [12438072.001]
  • [Cites] Jpn J Clin Oncol. 2004 Apr;34(4):210-4 [15121758.001]
  • [Cites] Br J Surg. 1970 Jul;57(7):529-30 [5427475.001]
  • [Cites] Urology. 1985 Apr;25(4):398-400 [2984822.001]
  • [Cites] AJR Am J Roentgenol. 1985 Dec;145(6):1165-71 [2998169.001]
  • [Cites] Dis Colon Rectum. 1987 Oct;30(10):805-8 [2820673.001]
  • [Cites] Ann Plast Surg. 1993 Oct;31(4):377-8 [8239441.001]
  • [Cites] Clin Orthop Relat Res. 1998 Oct;(355):272-81 [9917613.001]
  • [Cites] Acta Neurol Belg. 2005 Sep;105(3):178-9 [16255156.001]
  • [Cites] Eur Urol. 2005 Dec;48(6):885-94 [16126333.001]
  • [Cites] Singapore Med J. 2007 Mar;48(3):e77-80 [17342276.001]
  • [Cites] Eur J Surg Oncol. 2007 May;33(4):508-11 [17081724.001]
  • [Cites] Cancer. 2008 Jan 1;112(1):193-203 [18040999.001]
  • [Cites] JAMA. 2008 Feb 13;299(6):672-84 [18270356.001]
  • [Cites] Ann Surg Oncol. 2000 Aug;7(7):526-34 [10947022.001]
  • (PMID = 19937408.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AFP protein, human; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins
  • [Number-of-references] 17
  • [Other-IDs] NLM/ PMC2919860
  •  go-up   go-down


53. Che Z, Nam W, Park WS, Kim HJ, Cha IH, Kim HS, Yook JI, Kim J, Lee SH: Intraosseous nerve sheath tumors in the jaws. Yonsei Med J; 2006 Apr 30;47(2):264-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neurofibroma is one of the most common nerve sheath tumors occurring in the soft tissue and generally appears in neurofibromatosis 1 (NF1 or von Recklinghausen's disease).
  • Malignant peripheral nerve sheath tumors (MPNSTs) are uncommon sarcomas that almost always arise in the soft tissue.
  • [MeSH-major] Bone Neoplasms / diagnosis. Jaw / radiography. Nerve Sheath Neoplasms / diagnosis. Neurofibroma / pathology. Sarcoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Child. Diagnosis, Differential. Female. Humans. Male. Neurofibromatoses / pathology. X-Rays

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Surg Oral Med Oral Pathol. 1977 Nov;44(5):731-43 [270070.001]
  • [Cites] J Oral Surg. 1977 Sep;35(9):733-8 [407340.001]
  • [Cites] Int J Oral Surg. 1981 Aug;10(4):293-7 [6809661.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1983 Mar;55(3):253-8 [6403900.001]
  • [Cites] Lab Invest. 1983 Sep;49(3):299-308 [6310227.001]
  • [Cites] J Oral Med. 1983 Jul-Sep;38(3):94-6 [6579248.001]
  • [Cites] Acta Pathol Microbiol Immunol Scand A. 1984 May;92(3):147-55 [6431750.001]
  • [Cites] J Oral Maxillofac Surg. 1989 Jan;47(1):65-8 [2642961.001]
  • [Cites] Br J Oral Maxillofac Surg. 1990 Oct;28(5):344-6 [2123398.001]
  • [Cites] J Craniomaxillofac Surg. 1991 Jan;19(1):40-6 [2019658.001]
  • [Cites] J Oral Maxillofac Surg. 1991 Nov;49(11):1243-6 [1941345.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1992 Apr;73(4):407-11 [1574299.001]
  • [Cites] Pediatr Dent. 1992 Sep-Oct;14(5):347-50 [1303541.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):203-10 [8000997.001]
  • [Cites] Arch Pathol Lab Med. 1995 Apr;119(4):367-70 [7726730.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996 Mar;81(3):361-7 [8653472.001]
  • [Cites] Skeletal Radiol. 1998 Jun;27(6):346-9 [9677654.001]
  • [Cites] J Pierre Fauchard Acad. 1994 Sep;8(3):107-9 [9791251.001]
  • [Cites] Am J Surg Pathol. 1998 Nov;22(11):1368-78 [9808129.001]
  • [Cites] Radiology. 1961 Jan;76:1-20 [13716855.001]
  • [Cites] Yonsei Med J. 2002 Feb;43(1):109-13 [11854940.001]
  • [Cites] Am J Clin Pathol. 1967 Jun;47(6):759-66 [6025077.001]
  • [Cites] Cancer. 1967 Nov;20(11):1992-2001 [4294037.001]
  • [Cites] J Oral Surg. 1970 Apr;28(4):305-9 [4907056.001]
  • [Cites] Yonsei Med J. 1973;14:49-52 [4804132.001]
  • [Cites] Trans Sect Otolaryngol Am Acad Ophthalmol Otolaryngol. 1975 Sep-Oct;80(5):459-64 [1198775.001]
  • [Cites] J Oral Surg. 1981 Feb;39(2):125-7 [6936528.001]
  • (PMID = 16642559.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2687639
  •  go-up   go-down


54. Kim YD, Lee CH, Lee MK, Jeong YJ, Kim JY, Park DY, Sol MY: Primary alveolar soft part sarcoma of the lung. J Korean Med Sci; 2007 Apr;22(2):369-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary alveolar soft part sarcoma of the lung.
  • Alveolar soft part sarcoma (ASPS) is a rare epithelial-like soft tissue sarcoma.
  • Primary pulmonary involvement of this sarcoma, without evidence of soft tissue tumor elsewhere, is very exceptional.
  • [MeSH-major] Lung Neoplasms / pathology. Lung Neoplasms / radiography. Pulmonary Alveoli / pathology. Pulmonary Alveoli / radiography. Sarcoma / pathology. Sarcoma / radiography
  • [MeSH-minor] Adult. Female. Humans. Rare Diseases / pathology. Rare Diseases / radiography. Soft Tissue Neoplasms / pathology. Soft Tissue Neoplasms / radiography

  • Genetic Alliance. consumer health - Alveolar Soft Part Sarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 2000 May;58(4):319-23 [10838498.001]
  • [Cites] Oncogene. 2001 Jan 4;20(1):48-57 [11244503.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):179-92 [11438465.001]
  • [Cites] Cancer. 1989 Jan 1;63(1):1-13 [2642727.001]
  • [Cites] Acta Pathol Jpn. 1991 Oct;41(10):771-7 [1812692.001]
  • [Cites] Hum Pathol. 1993 Sep;24(9):1030-4 [8253458.001]
  • [Cites] Ann Pathol. 1996;16(1):49-52 [8652002.001]
  • [Cites] Adv Anat Pathol. 1999 May;6(3):125-39 [10342010.001]
  • (PMID = 17449953.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2693611
  •  go-up   go-down


55. Poveda A, López-Pousa A, Martín J, Del Muro JG, Bernabé R, Casado A, Balañá C, Sanmartín O, Menéndez MD, Escudero P, Cruz J, Belyakova E, Menéndez D, Buesa JM: Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX(R)/Doxil(R)) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS). Sarcoma; 2005;9(3-4):127-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX(R)/Doxil(R)) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS).
  • BACKGROUND: Pegylated liposomal doxorubicin (PLD), a formulation with pharmacokinetic differences with respect to doxorubicin (DXR), might benefit patients with advanced soft tissue sarcoma (STS) pretreated with DXR.
  • PATIENTS AND METHODS: Patients with measurable and progressive STS received PLD at 35 mg/(2) every 3 weeks.
  • CONCLUSIONS: PLD did not induce objective remissions in 22 STS patients pretreated with DXR, but progression-free rate figures support the use of this agent in patients who have not progressed under a DXR-containing regimen.

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18521419.001).
  • [ISSN] 1357-714X
  • [Journal-full-title] Sarcoma
  • [ISO-abbreviation] Sarcoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2395634
  •  go-up   go-down


56. López-Pousa A, Losa R, Martín J, Maurel J, Fra J, Sierra M, Casado A, García Del Muro J, Poveda A, Balañá C, Martínez-Trufero J, Esteban E, Buesa JM: Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study. Br J Cancer; 2006 Jun 19;94(12):1797-802
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study.
  • The aim of the study was to determine the dose-limiting toxicity and maximum tolerated dose of a first-line combination of doxorubicin and gemcitabine in adult patients with advanced soft tissue sarcomas and to explore its activity and toxicity, and the presence of possible interactions between these agents.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Deoxycytidine / metabolism. Deoxycytidine / pharmacokinetics. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Doxorubicin / metabolism. Doxorubicin / pharmacokinetics. Drug Interactions. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Oct;81(4):609-15 [10574245.001]
  • [Cites] Invest New Drugs. 1997;15(4):331-41 [9547676.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;45(2):177-81 [10663634.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2081-6 [10811673.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2545-52 [10893285.001]
  • [Cites] Anticancer Drugs. 2000 Jun;11(5):325-9 [10912948.001]
  • [Cites] Ann Hematol. 2000 Sep;79(9):485-92 [11043419.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3483-9 [11481354.001]
  • [Cites] Semin Oncol. 2001 Jun;28(3 Suppl 10):57-61 [11510035.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):556-9 [11872349.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2824-31 [12065559.001]
  • [Cites] Ann Oncol. 2002 Jun;13(6):919-27 [12123338.001]
  • [Cites] Ann Oncol. 2002 Nov;13(11):1771-8 [12419750.001]
  • [Cites] Cancer. 2003 Apr 15;97(8):1969-73 [12673725.001]
  • [Cites] Ann Oncol. 1998 Sep;9(9):1003-8 [9818075.001]
  • [Cites] Clin Ter. 1999 Jan-Feb;150(1):17-20 [10367540.001]
  • [Cites] Cancer. 2004 Nov 15;101(10):2261-9 [15484216.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1500-7 [14977854.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1706-12 [15117993.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):2936-43 [15131028.001]
  • [Cites] J Chromatogr. 1988 Jan 22;424(1):103-10 [3163337.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Cancer. 1990 Sep 1;66(5):862-7 [2201431.001]
  • [Cites] Cancer Chemother Pharmacol. 1991;27(4):258-62 [1998982.001]
  • [Cites] J Clin Oncol. 1991 Mar;9(3):491-8 [1999720.001]
  • [Cites] Ann Oncol. 1994 Jul;5(6):539-42 [7918126.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1537-45 [7602342.001]
  • [Cites] Semin Oncol. 1995 Aug;22(4 Suppl 11):3-10 [7481842.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • (PMID = 16721358.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 80168379AG / Doxorubicin; B76N6SBZ8R / gemcitabine
  • [Other-IDs] NLM/ PMC2361345
  •  go-up   go-down


57. Al-Refaie WB, Habermann EB, Jensen EH, Tuttle TM, Pisters PW, Virnig BA: Surgery alone is adequate treatment for early stage soft tissue sarcoma of the extremity. Br J Surg; 2010 May;97(5):707-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery alone is adequate treatment for early stage soft tissue sarcoma of the extremity.
  • BACKGROUND: Evolving evidence suggests that, in selected patients with tumour category 1 (T1) extremity soft tissue sarcoma (ESTS), surgery alone offers satisfactory results without decreasing survival.
  • This study assessed the effect of sarcoma treatments on survival outcomes of T1 ESTS in a population-based data set.
  • Multivariable analysis was used to assess the impact of radiotherapy on overall survival (OS) and sarcoma-specific survival (SSS), adjusting for co-variables.
  • [MeSH-major] Extremities. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Epidemiologic Methods. Female. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 British Journal of Surgery Society Ltd.
  • (PMID = 20235085.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


58. Agarwal N, Kaur N, Panwar P, Singh B: Synovial sarcoma of the thigh mimicking chronic cystic hematoma: a rare manifestation. J BUON; 2010 Jan-Mar;15(1):192
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synovial sarcoma of the thigh mimicking chronic cystic hematoma: a rare manifestation.
  • [MeSH-major] Cysts / diagnosis. Hematoma / diagnosis. Sarcoma, Synovial / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Biopsy. Chemotherapy, Adjuvant. Chronic Disease. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant. Reoperation. Thigh. Young Adult

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20414952.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Greece
  •  go-up   go-down


59. Sultan I, Rodriguez-Galindo C, Saab R, Yasir S, Casanova M, Ferrari A: Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology, and End Results program, 1983 to 2005: an analysis of 1268 patients. Cancer; 2009 Aug 1;115(15):3537-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology, and End Results program, 1983 to 2005: an analysis of 1268 patients.
  • BACKGROUND: Synovial sarcoma (SS) is a typical soft tissue sarcoma subtype crosswise between the pediatric and the adult age groups.
  • Less satisfactory overall outcome has been recorded in adult series.
  • In multivariate analysis, adult patients had significantly higher mortality rates than children after adjusting for other variables.
  • CONCLUSIONS: Children and adults with SS have a similar clinical presentation but a dissimilar outcome, suggesting that factors other than unfavorable clinical features might be involved in the unsatisfactory outcome of adult SS patients.
  • It remains to be ascertained whether this difference is related to biological variables or to historically different treatment approaches adopted in pediatric versus adult patients.
  • [MeSH-major] Sarcoma, Synovial / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged. Prognosis. SEER Program. Treatment Outcome

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 American Cancer Society.
  • (PMID = 19514087.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Matsuo T, Sugita T, Shimose S, Kubo T, Ishikawa M, Yasunaga Y, Ochi M: Immunohistochemical expression of promyelocytic leukemia body in soft tissue sarcomas. J Exp Clin Cancer Res; 2008;27:73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of promyelocytic leukemia body in soft tissue sarcomas.
  • PML body expression rates of all sarcoma cells were 1.5 +/- 1.8% (range: 0-7.0) in MFH and 1.3 +/- 1.4% (0-5.2) in liposarcoma samples.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Jul 13;406(6792):207-10 [10910364.001]
  • [Cites] Cancer Lett. 2003 May 15;194(2):155-62 [12757973.001]
  • [Cites] Nat Cell Biol. 2000 Oct;2(10):730-6 [11025664.001]
  • [Cites] Cell Death Differ. 2003 Dec;10(12):1290-9 [12934066.001]
  • [Cites] Oncogene. 2004 Apr 12;23(16):2819-24 [15077145.001]
  • [Cites] Am J Pathol. 2004 Aug;165(2):471-80 [15277221.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Oct;41(2):155-62 [15287028.001]
  • [Cites] Nature. 1990 Oct 11;347(6293):558-61 [2170850.001]
  • [Cites] Cell. 1991 Aug 23;66(4):663-74 [1652368.001]
  • [Cites] Cell. 1991 Aug 23;66(4):675-84 [1652369.001]
  • [Cites] EMBO J. 1992 Apr;11(4):1397-407 [1314166.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):4840-4 [1317574.001]
  • [Cites] N Engl J Med. 1993 Jul 15;329(3):177-89 [8515790.001]
  • [Cites] Blood. 1994 Jan 1;83(1):10-25 [8274729.001]
  • [Cites] Cancer Res. 1995 Apr 1;55(7):1590-7 [7882370.001]
  • [Cites] EMBO J. 1995 Sep 1;14(17):4240-8 [7556065.001]
  • [Cites] J Cancer Res Clin Oncol. 1995;121(9-10):555-63 [7559736.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1679-89 [8622088.001]
  • [Cites] Am J Pathol. 1996 Dec;149(6):2023-35 [8952536.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):350-62 [8996162.001]
  • [Cites] Nat Med. 1997 Nov;3(11):1271-4 [9359704.001]
  • [Cites] Oncogene. 1998 Jun 4;16(22):2905-13 [9671411.001]
  • [Cites] Am J Hum Genet. 1998 Aug;63(2):297-304 [9683622.001]
  • [Cites] Nat Genet. 1998 Nov;20(3):266-72 [9806545.001]
  • [Cites] Blood. 1999 May 15;93(10):3167-215 [10233871.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):217-25 [15671549.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2722-9 [15805271.001]
  • [Cites] Int J Cancer. 2005 Jul 1;115(4):556-60 [15688424.001]
  • [Cites] Cancer Lett. 2006 Jan 18;231(2):176-84 [16399222.001]
  • [Cites] Nature. 2006 Aug 17;442(7104):779-85 [16915281.001]
  • [Cites] Cell Res. 2008 Jun;18(6):622-40 [18504460.001]
  • [Cites] EMBO J. 2000 Nov 15;19(22):6185-95 [11080164.001]
  • [Cites] EMBO J. 2001 Aug 15;20(16):4547-59 [11500381.001]
  • [Cites] Oncogene. 2001 Oct 29;20(49):7257-65 [11704854.001]
  • [Cites] Cell. 2002 Jan 25;108(2):165-70 [11832207.001]
  • [Cites] Differentiation. 2002 Mar;70(1):10-22 [11963652.001]
  • [Cites] EMBO J. 2002 Jul 1;21(13):3358-69 [12093737.001]
  • [Cites] Mol Cell Biol. 2002 Aug;22(15):5259-69 [12101223.001]
  • [Cites] Cancer Cell. 2002 Oct;2(4):257-65 [12398889.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1759-63 [12702558.001]
  • [Cites] Genes Dev. 2000 Aug 15;14(16):2015-27 [10950866.001]
  • (PMID = 19025608.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 143220-95-5 / PML protein, human
  • [Other-IDs] NLM/ PMC2611968
  •  go-up   go-down


61. Chung L, Lau SK, Jiang Z, Loera S, Bedel V, Ji J, Weiss LM, Chu PG: Overlapping features between dedifferentiated liposarcoma and undifferentiated high-grade pleomorphic sarcoma. Am J Surg Pathol; 2009 Nov;33(11):1594-600
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overlapping features between dedifferentiated liposarcoma and undifferentiated high-grade pleomorphic sarcoma.
  • Dedifferentiated liposarcoma (DDL), occurring in up to 10% of well differentiated liposarcoma cases, has similar histologic features to that of undifferentiated high-grade pleomorphic sarcoma (UHGPS); the former develops in a background of atypical lipomatous tumors/well differentiated liposarcoma, whereas the latter shows no specific line of differentiation.
  • [MeSH-major] Liposarcoma / diagnosis. Retroperitoneal Neoplasms / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Adipocytes / metabolism. Adipocytes / pathology. Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Cell Nucleus / metabolism. Cell Nucleus / pathology. Cyclin-Dependent Kinase 4 / metabolism. Diagnosis, Differential. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Liposarcoma, Myxoid / diagnosis. Liposarcoma, Myxoid / metabolism. Liposarcoma, Myxoid / surgery. Male. Middle Aged. PPAR gamma / metabolism. Proto-Oncogene Proteins c-mdm2 / metabolism. Thigh. Young Adult

  • Genetic Alliance. consumer health - Liposarcoma.
  • Genetic Alliance. consumer health - Pleomorphic Undifferentiated Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19574885.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PPAR gamma; EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


62. Grabellus F, Sheu SY, Tötsch M, Lehmann N, Kaiser GM, Jasani B, Taeger G, Schmid KW: Overexpression of the drug resistance-associated protein metallothionein does not correlate with response of sarcomas to isolated limb perfusion treatment. J Surg Oncol; 2010 May 1;101(6):465-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Objective of this study was to investigate the influence of MT expression on tumor responses in HILP-TM-treated soft tissue (STSs) and bone sarcomas (BS).
  • [MeSH-major] Bone Neoplasms / drug therapy. Bone Neoplasms / metabolism. Chemotherapy, Cancer, Regional Perfusion. Drug Resistance, Neoplasm. Metallothionein / analysis. Sarcoma / drug therapy. Sarcoma / metabolism. Soft Tissue Neoplasms / drug therapy. Soft Tissue Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents, Alkylating / administration & dosage. Female. Humans. Immunohistochemistry. Male. Melphalan / administration & dosage. Middle Aged. Tumor Necrosis Factor-alpha / administration & dosage

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20401916.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Necrosis Factor-alpha; 9038-94-2 / Metallothionein; Q41OR9510P / Melphalan
  •  go-up   go-down


63. de Visscher SA, van Ginkel RJ, Wobbes T, Veth RP, Ten Heuvel SE, Suurmeijer AJ, Hoekstra HJ: Epithelioid sarcoma: Still an only surgically curable disease. Cancer; 2006 Aug 1;107(3):606-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelioid sarcoma: Still an only surgically curable disease.
  • BACKGROUND: Epithelioid sarcoma is a rare soft tissue sarcoma with a known high propensity for locoregional recurrence and distant metastases.
  • The clinical behavior and prognostic factors that influence the survival of patients with epithelioid sarcoma were studied.
  • METHODS: Twenty-three patients, including 16 men (70%) and 7 women (30%), who were treated for epithelioid sarcoma between 1979-2003 at the University Medical Center Groningen and Radboud University Nijmegen Medical Center, were reviewed retrospectively.
  • CONCLUSIONS: The prognosis for patients with epithelioid sarcoma is poor, because a substantial number of patients present with extensive disease, lymph node metastases, and/or distant metastases.
  • [MeSH-major] Epithelioid Cells / pathology. Sarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Middle Aged. Neoplasm Staging. Netherlands. Prognosis. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Epithelioid Sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16804932.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Papagelopoulos PJ, Mavrogenis AF, Mastorakos DP, Vlastou C, Vrouvas J, Soucacos PN: Free vascularised tissue transfer and brachytherapy for soft-tissue sarcomas of the extremities. Injury; 2008 Sep;39 Suppl 3:S83-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Free vascularised tissue transfer and brachytherapy for soft-tissue sarcomas of the extremities.
  • SUMMARY: We reviewed the medical files of nine patients with localised soft-tissue sarcomas of the extremities treated with surgical resection, free vascularised tissue transfer, and computerised after-loading iridium-192 high dose rate brachytherapy over a period of 8 years.
  • Microsurgical reconstruction of the soft-tissue defect used a free vascularised musculocutaneous flap that included the gracilis flap in five patients, the latissimus dorsi flap in four patients, and the radiovolar flap in one patient.
  • Tumour resection for soft-tissue sarcomas combined with microsurgical reconstruction of the soft-tissue defect, preoperative external beam radiation and high dose rate brachytherapy results in a high degree of local control with acceptable complications.
  • [MeSH-major] Brachytherapy / methods. Extremities / surgery. Sarcoma / surgery. Soft Tissue Neoplasms / surgery. Surgical Flaps / blood supply
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Dose Fractionation. Female. Follow-Up Studies. Humans. Limb Salvage / methods. Male. Microsurgery / methods. Middle Aged. Muscle, Skeletal / transplantation. Reconstructive Surgical Procedures / methods. Skin Transplantation / methods. Young Adult

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18687428.001).
  • [ISSN] 1879-0267
  • [Journal-full-title] Injury
  • [ISO-abbreviation] Injury
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


65. Hajdu M, Singer S, Maki RG, Schwartz GK, Keohan ML, Antonescu CR: IGF2 over-expression in solitary fibrous tumours is independent of anatomical location and is related to loss of imprinting. J Pathol; 2010 Jul;221(3):300-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The transcriptional signature was compared to a set of 34 soft tissue sarcomas spanning seven subtypes.
  • SFT had a distinct expression signature and clustered in a tight genomic cluster, separate from all other sarcoma subtypes.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Cancer Res. 2009 Sep 15;69(18):7175-9 [19723655.001]
  • [Cites] Cancer. 2002 Feb 15;94(4):1057-68 [11920476.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12877-82 [12297622.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):691-700 [12875988.001]
  • [Cites] Hum Mol Genet. 2004 Jan 1;13(1):69-78 [14613973.001]
  • [Cites] Med Oncol. 2003;20(4):403-8 [14716039.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3282-90 [15161681.001]
  • [Cites] Nucleic Acids Res. 1991 Dec 25;19(24):6967 [1684848.001]
  • [Cites] Cancer. 1993 May 15;71(10):3009-13 [8490829.001]
  • [Cites] FASEB J. 1999;13 Suppl:S77-82 [10352148.001]
  • [Cites] PLoS Biol. 2005 Jun;3(6):e187 [15869330.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 4;102(40):14344-9 [16186508.001]
  • [Cites] Am J Pathol. 2006 Mar;168(3):866-77 [16507902.001]
  • [Cites] Chest. 2006 Aug;130(2):581-3 [16899864.001]
  • [Cites] Oral Oncol. 2007 Jan;43(1):60-6 [16807070.001]
  • [Cites] J Pathol. 2007 Apr;211(5):550-4 [17299733.001]
  • [Cites] Biochim Biophys Acta. 2008 Jan;1785(1):12-31 [18031935.001]
  • [Cites] Cancer Res. 2008 Feb 1;68(3):664-73 [18245465.001]
  • [Cites] Blood. 2008 May 1;111(9):4788-96 [18252861.001]
  • [Cites] Cell Cycle. 2009 Feb 15;8(4):580-8 [19182515.001]
  • [Cites] Curr Opin Oncol. 2009 Jul;21(4):327-31 [19444101.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Jul;94(7):2226-31 [19383775.001]
  • [Cites] Endocr Relat Cancer. 2009 Sep;16(3):939-52 [19502451.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Nov;131(1):69-73 [11734322.001]
  • (PMID = 20527023.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA148260; United States / NCI NIH HHS / CA / P01CA47179; United States / NCI NIH HHS / CA / RC2 CA148260-01; United States / NCI NIH HHS / CA / RC2 CA148260; United States / NCI NIH HHS / CA / P01 CA047179-18; United States / CCR NIH HHS / RC / CA148260-01; United States / NCI NIH HHS / CA / P01 CA047179
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / FGFR1OP protein, human; 0 / IGF2 protein, human; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins; 67763-97-7 / Insulin-Like Growth Factor II; EC 2.7.10.1 / DDR1 protein, human; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ NIHMS349582; NLM/ PMC3264680
  •  go-up   go-down


66. Meng GZ, Zhang HY, Bu H, Zhang XL, Pang ZG, Ke Q, Liu X, Yang G: Myofibroblastic sarcomas: a clinicopathological study of 20 cases. Chin Med J (Engl); 2007 Mar 5;120(5):363-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Myofibroblastic sarcoma was used to be a controversial neoplasm.
  • This study investigated the clinicopathological features of 20 cases of myofibroblastic sarcoma arising in different locations.
  • METHODS: The paraffin-embedded tissue samples from 20 cases of patients with myofibroblastic sarcoma were stained immunohistochemically, and 5 cases examined by electron microscopy.
  • [MeSH-major] Fibrosarcoma / pathology. Myosarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Desmin / analysis. Female. Humans. Immunohistochemistry. Male. Middle Aged. Recurrence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17376304.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Desmin
  •  go-up   go-down


67. Adkison JB, Kuske RR, Patel RR: Breast conserving surgery and accelerated partial breast irradiation after prior breast radiation therapy. Am J Clin Oncol; 2010 Oct;33(5):427-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Six patients were previously treated for Hodgkin disease, 4 for invasive or in situ breast cancer, and 1 for soft tissue sarcoma.
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Patient Satisfaction. Radiotherapy, Computer-Assisted. Recurrence. Reoperation. Survival Analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19884802.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Cherix S, Speiser M, Matter M, Raffoul W, Liénard D, Theumann N, Mouhsine E, Mirimanoff RO, Leyvraz S, Lejeune FJ, Leyvraz PF: Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients. J Surg Oncol; 2008 Sep 1;98(3):148-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients.
  • BACKGROUND AND OBJECTIVES: Isolated limb perfusion with TNF-alpha and melphalan (TM-ILP) is a limb salvage therapy for non-resectable soft tissue sarcomas (STS) of the extremities.
  • CONCLUSIONS: TM-ILP is a conservative treatment with a high complications rate, but it can be successful even for the most severe STS of extremities.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Chemotherapy, Cancer, Regional Perfusion. Limb Salvage. Melphalan / administration & dosage. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy. Tumor Necrosis Factor-alpha / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18668638.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  •  go-up   go-down


69. Tran PT, Hara W, Su Z, Lin HJ, Bendapudi PK, Norton J, Teng N, King CR, Kapp DS: Intraoperative radiation therapy for locally advanced and recurrent soft-tissue sarcomas in adults. Int J Radiat Oncol Biol Phys; 2008 Nov 15;72(4):1146-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative radiation therapy for locally advanced and recurrent soft-tissue sarcomas in adults.
  • PURPOSE: To analyze the outcomes of and identify prognostic factors for patients treated with surgery and intraoperative radiotherapy (IORT) for locally advanced and recurrent soft-tissue sarcoma in adults from a single institution.
  • [MeSH-major] Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Sarcoma / radiotherapy. Sarcoma / surgery. Soft Tissue Neoplasms / radiotherapy. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. California / epidemiology. Humans. Incidence. Intraoperative Care / methods. Male. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Survival Rate

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18394818.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


70. Billings SD, Giblen G, Fanburg-Smith JC: Superficial low-grade fibromyxoid sarcoma (Evans tumor): a clinicopathologic analysis of 19 cases with a unique observation in the pediatric population. Am J Surg Pathol; 2005 Feb;29(2):204-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superficial low-grade fibromyxoid sarcoma (Evans tumor): a clinicopathologic analysis of 19 cases with a unique observation in the pediatric population.
  • Low-grade fibromyxoid sarcoma (LGFMS), usually a deeply situated mass in adults, is uncommon in superficial soft tissue and in children.
  • Clinical and histologic submitting diagnoses were mainly benign except for 3 cases, submitted as low-grade sarcoma, with only one as superficial LGFMS.
  • [MeSH-major] Fibroma / pathology. Sarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15644777.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Kim T, Choi YL, Park HY, Song JY, Shin JH, Nam SJ, Ahn G: Dermatofibrosarcoma protuberans of the breast skin. Pathol Int; 2010 Dec;60(12):784-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ultrasonography and biopsy demonstrated a possibility of sarcoma of the breast.
  • It is important to diagnose a soft tissue lesion accurately when it occurs in the breast.
  • [MeSH-minor] Adult. Dermatofibrosarcoma / genetics. Dermatofibrosarcoma / metabolism. Dermatofibrosarcoma / pathology. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Proto-Oncogene Proteins c-sis / biosynthesis. Proto-Oncogene Proteins c-sis / genetics

  • Genetic Alliance. consumer health - Dermatofibrosarcoma Protuberans.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Pathology International © 2010 Japanese Society of Pathology and Blackwell Publishing Asia Pty Ltd.
  • (PMID = 21091837.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-sis
  •  go-up   go-down


72. Moretti VM, Brooks JS, Ogilvie CM: Case report: hemosiderotic fibrohistiocytic lipomatous lesion: a clinicopathologic characterization. Clin Orthop Relat Res; 2010 Oct;468(10):2808-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Hemosiderosis / pathology. Histiocytic Disorders, Malignant / pathology. Lipoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Foot. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2000 Nov;13(11):1192-9 [11106076.001]
  • [Cites] AJR Am J Roentgenol. 2004 Mar;182(3):733-9 [14975977.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1417-25 [15489645.001]
  • [Cites] Skeletal Radiol. 1997 Mar;26(3):150-4 [9108224.001]
  • [Cites] J Pathol. 2009 Apr;217(5):716-27 [19199331.001]
  • [Cites] Histopathology. 2006 Mar;48(4):453-61 [16487368.001]
  • [Cites] Pathol Int. 2006 May;56(5):283-6 [16669878.001]
  • [Cites] Skeletal Radiol. 2008 Jan;37(1):71-4 [17968543.001]
  • [Cites] Cancer Genet Cytogenet. 2008 Apr 15;182(2):140-3 [18406878.001]
  • [Cites] Virchows Arch. 2005 Jul;447(1):103-6 [15947948.001]
  • (PMID = 20127213.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 11
  • [Other-IDs] NLM/ PMC3049609
  •  go-up   go-down


73. Stoeckle E, Gardet H, Coindre JM, Kantor G, Bonichon F, Milbéo Y, Thomas L, Avril A, Bui BN: Prospective evaluation of quality of surgery in soft tissue sarcoma. Eur J Surg Oncol; 2006 Dec;32(10):1242-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective evaluation of quality of surgery in soft tissue sarcoma.
  • BACKGROUND: Prospective application of the French Sarcoma Group (FSG) method of surgery reporting in soft tissue sarcoma (STS) in a single centre.
  • METHODS: Patients with primary STS of the extremities or trunk wall consecutively operated at the same institution from January 1996 to December 2002 were evaluated for local recurrence (LR).
  • CONCLUSION: This first prospective evaluation of surgery reporting in STS evidences a fourfold, highly discriminating difference in LR between resections R0 and R1.
  • [MeSH-major] Extremities. Neoplasm Recurrence, Local. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm, Residual. Prognosis. Risk Factors

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793237.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


74. Rüdiger HA, Beltrami G, Campanacci DA, Mela MM, Franchi A, Capanna R: Soft tissue sarcomas of the popliteal fossa: outcome and risk factors. Eur J Surg Oncol; 2007 May;33(4):512-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue sarcomas of the popliteal fossa: outcome and risk factors.
  • BACKGROUND: Limb salvage surgery of popliteal soft tissue sarcomas may be hampered due to the incomplete anatomical containment of this region and the vicinity of neurovascular structures.
  • PATIENTS AND METHODS: 27 patients (53.3+/-15.8 y; 16/27 male) with popliteal soft tissue sarcomas were assessed.
  • [MeSH-major] Leg. Limb Salvage / methods. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Amputation. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Risk Factors. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17174515.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


75. Srivastava A, Rosenberg AE, Selig M, Rubin BP, Nielsen GP: Keratin-positive Ewing's sarcoma: an ultrastructural study of 12 cases. Int J Surg Pathol; 2005 Jan;13(1):43-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Keratin-positive Ewing's sarcoma: an ultrastructural study of 12 cases.
  • Ewing's sarcoma/primitive neuroectodermal tumor (EWS/PNET) is an aggressive neoplasm of bone and soft tissue.
  • [MeSH-major] Bone Neoplasms / ultrastructure. Keratins. Neuroectodermal Tumors, Primitive, Peripheral / ultrastructure. Sarcoma, Ewing / ultrastructure. Soft Tissue Neoplasms / ultrastructure
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / analysis. Child. Fatal Outcome. Female. Humans. Immunohistochemistry. Male. Microscopy, Electron, Transmission. Oncogene Proteins, Fusion / genetics. Proto-Oncogene Protein c-fli-1. RNA, Neoplasm / analysis. RNA-Binding Protein EWS. Reverse Transcriptase Polymerase Chain Reaction. Transcription Factors / genetics

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735854.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / EWS-FLI fusion protein; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Protein c-fli-1; 0 / RNA, Neoplasm; 0 / RNA-Binding Protein EWS; 0 / Transcription Factors; 68238-35-7 / Keratins
  •  go-up   go-down


76. Sakellaridis N, Mahera H, Pomonis S: Hemangiopericytoma-like synovial sarcoma of the lumbar spine. Case report. J Neurosurg Spine; 2006 Feb;4(2):179-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemangiopericytoma-like synovial sarcoma of the lumbar spine. Case report.
  • The purpose of this report is to demonstrate that synovial sarcoma should be included in the differential diagnosis of tumors originating from the lumbar spine, especially if they show hemangiopericytoma-like pathological characteristics.
  • A synovial sarcoma is a mesenchymal spindle cell tumor that displays variable epithelial differentiation including glandular formation.
  • More than 80% of these lesions arise in the deep soft tissue of the extremities.
  • During repeated operation, this lesion was shown to be a synovial sarcoma, which had invaded the dura mater.
  • To the authors' knowledge, this is the first reported case of a synovial sarcoma originating from the lumbar spine.
  • [MeSH-major] Hemangiopericytoma / diagnosis. Sarcoma, Synovial / diagnosis. Spinal Cord Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Dura Mater / pathology. Female. Humans. Lumbosacral Region. Neoplasm Invasiveness. Neoplasm Metastasis. Reoperation

  • Genetic Alliance. consumer health - Hemangiopericytoma.
  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16506487.001).
  • [ISSN] 1547-5654
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Coindre JM: [Molecular diagnosis of routine sarcomas]. Ann Pathol; 2008 Nov;28 Spec No 1(1):S64-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Genetic Techniques. Sarcoma / diagnosis
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Bone Neoplasms / diagnosis. Bone Neoplasms / genetics. Bone Neoplasms / pathology. Child. Humans. Rhabdomyosarcoma, Alveolar / diagnosis. Rhabdomyosarcoma, Alveolar / genetics. Rhabdomyosarcoma, Alveolar / pathology. Sarcoma, Ewing / diagnosis. Sarcoma, Ewing / genetics. Sarcoma, Ewing / pathology. Sarcoma, Synovial / diagnosis. Sarcoma, Synovial / genetics. Sarcoma, Synovial / pathology. Soft Tissue Neoplasms / diagnosis. Soft Tissue Neoplasms / genetics. Soft Tissue Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18984305.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


78. Nathan PC, Tsokos M, Long L, Bernstein D, Wexler LH, Mackall CL, Helman LJ: Adjuvant chemotherapy for the treatment of advanced pediatric nonrhabdomyosarcoma soft tissue sarcoma: the National Cancer Institute experience. Pediatr Blood Cancer; 2005 May;44(5):449-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy for the treatment of advanced pediatric nonrhabdomyosarcoma soft tissue sarcoma: the National Cancer Institute experience.
  • BACKGROUND: The survival of children and adolescents with advanced (unresectable or metastatic) nonrhabdomyosarcoma soft tissue sarcoma (NRSTS) is poor.
  • [MeSH-major] Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Doxorubicin / therapeutic use. Female. Humans. Infant. Male. Neoplasm Metastasis. Remission Induction / methods. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published 2004 Wiley-Liss, Inc.
  • [CommentIn] Pediatr Blood Cancer. 2005 Aug;45(2):226-7; author reply 228 [15782404.001]
  • (PMID = 15547929.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin
  •  go-up   go-down


79. Nielsen OS, Reichardt P, Christensen TB, Pink D, Daugaard S, Hermans C, Marreaud S, van Glabbeke M, Blay J, Judson I: Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas. Eur J Cancer; 2006 Sep;42(14):2303-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas.
  • This phase I study evaluated the toxicity of first-line combined pegylated liposomal doxorubicin (Caelyx) and ifosfamide in patients with advanced and/or metastatic soft tissue sarcomas.
  • In conclusion, this seems to be a feasible combination in patients with advanced soft tissue sarcomas, allowing ifosfamide to be given in a dosage similar to that used when given alone.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Sarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Male. Middle Aged. Neoplasm Metastasis. Treatment Outcome

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16891112.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


80. Fanburg-Smith JC, Majidi M, Miettinen M: Keratin expression in schwannoma; a study of 115 retroperitoneal and 22 peripheral schwannomas. Mod Pathol; 2006 Jan;19(1):115-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We conclude that crossreactivity of AE1/AE3 with other intermediate filament proteins, such as GFAP, as previously observed in brain and glioma tissue, probably accounts for the extensive keratin-positivity seen in some retroperitoneal schwannomas.
  • Keratin-positive schwannomas should not be confused with other keratin-positive tumors, such as sarcomatoid carcinoma, mesothelioma, and synovial sarcoma.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Glial Fibrillary Acidic Protein / analysis. Humans. Immunohistochemistry. Male. Middle Aged

  • Genetic Alliance. consumer health - Schwannoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16357842.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 68238-35-7 / Keratins
  •  go-up   go-down


81. Marcon N, Montagne K, Corby S, Ayav A, Plénat F, Champigneulle J: [Primary clear cell sarcoma of the ileum]. Ann Pathol; 2007 Oct;27(5):369-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary clear cell sarcoma of the ileum].
  • Clear cell sarcoma or malignant melanoma of soft tissue is a high-grade sarcoma with melanocytic differentiation, essentially involving tendons and aponeuroses of distal extremities in young adults.
  • We present a case of an ileal clear cell sarcoma discovered in a 26-year-old woman.
  • Moreover, we emphasize on the diagnosis difficulties of this rare type of sarcoma, characterized by the specific translocation t(12;22)(q13;q12).
  • [MeSH-major] Ileal Neoplasms / pathology. Sarcoma, Clear Cell / pathology
  • [MeSH-minor] Adult. Antigens, CD / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18185472.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


82. Antonescu CR, Dal Cin P, Nafa K, Teot LA, Surti U, Fletcher CD, Ladanyi M: EWSR1-CREB1 is the predominant gene fusion in angiomatoid fibrous histiocytoma. Genes Chromosomes Cancer; 2007 Dec;46(12):1051-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EWSR1-CREB1 is a novel translocation recently described in clear cell sarcoma of the GI tract.
  • EWSR1-ATF1, identified in some AFH cases, is the most common genetic abnormality in soft tissue clear cell sarcoma.
  • Thus, identical fusions involving ATF1 and CREB1 are found in two distinct sarcomas, which may be able to transform two different types of mesenchymal precursor cells, unlike most other sarcoma gene fusions.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Cytogenetic Analysis. Female. Gene Expression. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Histiocytoma, angiomatoid fibrous.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17724745.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CREB1 protein, human; 0 / Calmodulin-Binding Proteins; 0 / Cyclic AMP Response Element-Binding Protein; 0 / EWSR1 protein, human; 0 / RNA-Binding Proteins
  •  go-up   go-down


83. Grochola LF, Vazquez A, Bond EE, Würl P, Taubert H, Müller TH, Levine AJ, Bond GL: Recent natural selection identifies a genetic variant in a regulatory subunit of protein phosphatase 2A that associates with altered cancer risk and survival. Clin Cancer Res; 2009 Oct 1;15(19):6301-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We go on to show that a selected SNP in PPP2R5E (epsilon-SNP2) associates with significant allelic differences in the onset (up to 19.2 years; P = 0.0002) and risk (odds ratio, up to 8.1; P = 0.0009) of soft tissue sarcoma development, as well as overall survival (relative risk, up to 3.04; P = 0.026).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Genetic Predisposition to Disease. Humans. Male. Middle Aged. Mutant Proteins / genetics. Mutant Proteins / physiology. Polymorphism, Single Nucleotide / physiology. Protein Subunits / genetics. Protein Subunits / physiology. Risk Factors. Survival Analysis. Time Factors. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19773383.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mutant Proteins; 0 / PPP2R5E protein, human; 0 / Protein Subunits; EC 3.1.3.16 / Protein Phosphatase 2
  •  go-up   go-down


84. Gronchi A, Casali PG, Mariani L, Miceli R, Fiore M, Lo Vullo S, Bertulli R, Collini P, Lozza L, Olmi P, Rosai J: Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities: a series of patients treated at a single institution. J Clin Oncol; 2005 Jan 1;23(1):96-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities: a series of patients treated at a single institution.
  • PURPOSE: To explore the prognostic effect of microscopic marginal status after surgery for extremity soft tissue sarcomas.
  • This would seem to justify a policy of surgical adequacy in adult soft tissue sarcomas, though clinical decision making in borderline presentations for conservative surgery might be reasonably flexible and shared with the patient.
  • [MeSH-major] Sarcoma / pathology. Sarcoma / surgery. Soft Tissue Neoplasms / pathology. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Arm. Female. Follow-Up Studies. Humans. Leg. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Prognosis

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15625364.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Folk GS, Williams SB, Foss RB, Fanburg-Smith JC: Oral and maxillofacial sclerosing epithelioid fibrosarcoma: report of five cases. Head Neck Pathol; 2007 Sep;1(1):13-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sclerosing epithelioid fibrosarcoma (SEF) has distinctive morphology and occurs mainly in deep soft tissue of adult extremities.
  • Inclusion required OMFR location, an abundantly sclerotic sarcoma with epithelioid features, and lack of other phenotype by immunohistochemistry.
  • Tumor location included the infra-temporal fossa, buccal mucosa (recurrence extending into bone), anterior mandible (intraosseous primary, focally extending into soft tissue), and left parotid and submandibular gland (with metaplastic bone) regions.
  • [MeSH-major] Facial Bones / pathology. Fibrosarcoma / pathology. Maxilla / pathology. Mouth Neoplasms / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Apoptosis. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Epithelioid Cells / metabolism. Epithelioid Cells / pathology. Female. Histiocytoma, Benign Fibrous / diagnosis. Humans. Leiomyoma / diagnosis. Male. Middle Aged. Sclerosis. Solitary Fibrous Tumors / diagnosis. Young Adult

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Genet Cytogenet. 2000 Jun;119(2):127-31 [10867148.001]
  • [Cites] Cancer. 1989 Aug 15;64(4):925-31 [2545330.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):699-709 [11395547.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1175-83 [12218574.001]
  • [Cites] Int J Surg Pathol. 2002 Jul;10(3):227-30 [12232581.001]
  • [Cites] J Clin Pathol. 2004 Jan;57(1):90-4 [14693846.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Jul 15;152(2):136-40 [15262433.001]
  • [Cites] Virchows Arch. 2004 Oct;445(4):410-3 [15322876.001]
  • [Cites] Neurosurgery. 2000 Oct;47(4):956-9; discussion 959-60 [11014436.001]
  • [Cites] Methods Enzymol. 1990;184:357-63 [1697021.001]
  • [Cites] Am J Surg Pathol. 1995 Sep;19(9):979-93 [7661286.001]
  • [Cites] Histopathology. 1996 May;28(5):451-5 [8735721.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):350-62 [8996162.001]
  • [Cites] Histopathology. 1998 Oct;33(4):354-60 [9822926.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Dec;107(2):102-6 [9844602.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2005 Feb;114(2):87-9 [15757185.001]
  • [ErratumIn] Head Neck Pathol. 2013 Mar;7(1):103
  • (PMID = 20614275.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2807507
  • [Keywords] NOTNLM ; Maxillofacial / Oral / Sarcoma / Sclerosing epithelioid fibrosarcoma
  •  go-up   go-down


86. Liu HY, Yin HL, DU J, Cai Y, Lu ZF, Zhou HB, Zhou XJ: [Clinicopathologic features of granulocytic sarcoma: a study of 38 cases]. Zhonghua Bing Li Xue Za Zhi; 2010 Mar;39(3):172-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic features of granulocytic sarcoma: a study of 38 cases].
  • OBJECTIVE: To study the clinicopathologic features of granulocytic sarcoma.
  • METHODS: The clinical and pathologic findings of 38 cases of granulocytic sarcoma were retrospectively analyzed.
  • Major clinical presentations included superficial lymph node enlargement and painful soft tissue mass.
  • CONCLUSIONS: Granulocytic sarcoma is a known histologic mimicker of non-Hodgkin lymphoma, Ewing sarcoma/PNET and embryonal rhabdomyosarcoma.
  • [MeSH-major] Muscle Neoplasms / pathology. Ovarian Neoplasms / pathology. Sarcoma, Myeloid / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD43 / metabolism. Burkitt Lymphoma / metabolism. Burkitt Lymphoma / pathology. Child. Child, Preschool. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Lymph Nodes / pathology. Male. Middle Aged. Peroxidase / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Retrospective Studies. Sarcoma, Ewing / metabolism. Sarcoma, Ewing / pathology. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20450763.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD43; EC 1.11.1.7 / Peroxidase
  •  go-up   go-down


87. Herzog CE: Overview of sarcomas in the adolescent and young adult population. J Pediatr Hematol Oncol; 2005 Apr;27(4):215-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overview of sarcomas in the adolescent and young adult population.
  • Based on the data of the Surveillance, Epidemiology and End Results Section of the National Cancer Institute (SEER) program, soft tissue and bone sarcomas account for about 1% of all new malignancies diagnosed in the United States each year.
  • However, there are numerous different histologic types, and any given type of sarcoma is extremely rare.
  • In an effort to estimate the frequency and absolute numbers of different sarcomas in the adolescent and young adult population, the University of Texas M. D.
  • Anderson Cancer Center (MDACC) tumor registry was queried for all soft tissue sarcomas from 1990 through 2003, and all bone sarcomas from 1990 through 2002.
  • Based on this query, an overview of sarcomas that occur predominantly in the adolescent and young adult (AYA) population is presented.
  • These sarcomas include rhabdomyosarcoma, synovial sarcoma, neurogenic sarcoma, epithelioid sarcomas, alveolar soft parts sarcoma, Ewing sarcoma, and osteosarcoma.
  • Using the percentages for occurrence of each histologic type determined from the MDACC database, and the SEER estimate of overall sarcoma incidence, an estimate of the number of new cases in 2004 for the predominant histologic types occurring in the AYA population are presented.
  • [MeSH-major] Bone Neoplasms / pathology. Sarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Humans. Middle Aged. SEER Program

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15838394.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


88. Borinstein SC, Pollard J, Winter L, Hawkins DS: Pegfilgrastim for prevention of chemotherapy-associated neutropenia in pediatric patients with solid tumors. Pediatr Blood Cancer; 2009 Sep;53(3):375-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary diagnoses included osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, soft tissue sarcoma, neuroblastoma, Hodgkin disease, and other solid tumors.
  • Eight patients were treated with interval-compressed (every 14 days) sarcoma chemotherapy.
  • [MeSH-minor] Adolescent. Adult. Bone Marrow / drug effects. Child. Child, Preschool. Female. Filgrastim. Health Care Costs. Humans. Infant. Male. Recombinant Proteins. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • Hazardous Substances Data Bank. Filgrastim .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19484756.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 2T32CA009351; United States / NCI NIH HHS / CA / 5K12CA076930-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3A58010674 / pegfilgrastim; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


89. Aranha O, Agulnik M: Molecularly targeted therapies in adult soft tissue sarcomas: present approach and future directions. Expert Opin Ther Targets; 2008 Feb;12(2):197-207
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecularly targeted therapies in adult soft tissue sarcomas: present approach and future directions.
  • Given the overwhelming chemotherapy resistance of the disease, patients with progressive and metastatic soft tissue sarcomas are ideal candidates for trials of investigational new drugs.
  • OBJECTIVE: The authors review the molecular mechanisms underlying soft tissue sarcomas and discuss molecularly targeted therapies developed to improve the poor outcome of these uncommon tumors.
  • METHODS: A Medline and American Society of Clinical Oncology abstract search was conducted using the keyword 'soft tissue sarcoma'.
  • Articles and abstracts were reviewed and eligible for inclusion if they used targeted therapies for the treatment of patients with soft tissue sarcomas.
  • RESULTS/CONCLUSION: Phase II clinical trials for patients with soft tissue sarcomas using novel targets and present recognized targets are ongoing and planned.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Drug Delivery Systems / methods. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Humans

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18208368.001).
  • [ISSN] 1744-7631
  • [Journal-full-title] Expert opinion on therapeutic targets
  • [ISO-abbreviation] Expert Opin. Ther. Targets
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 80
  •  go-up   go-down


90. Burke M, Anderson JR, Kao SC, Rodeberg D, Qualman SJ, Wolden SL, Meyer WH, Breitfeld PP, Soft Tissue Sarcoma Committee of the Children's Oncology Group: Assessment of response to induction therapy and its influence on 5-year failure-free survival in group III rhabdomyosarcoma: the Intergroup Rhabdomyosarcoma Study-IV experience--a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol; 2007 Nov 1;25(31):4909-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of response to induction therapy and its influence on 5-year failure-free survival in group III rhabdomyosarcoma: the Intergroup Rhabdomyosarcoma Study-IV experience--a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
  • PURPOSE: Initial response to induction chemotherapy predicts failure-free survival (FFS) in osteosarcoma and Ewing's sarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Neoadjuvant Therapy. Rhabdomyosarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Dose Fractionation. Female. Humans. Infant. Male. Survival Analysis

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17971587.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 98543; United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / U10 CA24507
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


91. Stepanova EV, Bokhian BIu, Petrovichev NN, Lichinitzer MR: [Thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in soft-tissue sarcoma versus capecitabine potential]. Vopr Onkol; 2005;51(3):314-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in soft-tissue sarcoma versus capecitabine potential].
  • High TP expression was observed in 35 (42%) patients with soft-tissue sarcoma.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Biomarkers, Tumor / analysis. Deoxycytidine / analogs & derivatives. Dihydrouracil Dehydrogenase (NADP) / analysis. Sarcoma / drug therapy. Thymidine Phosphorylase / analysis. Thymidylate Synthase / analysis
  • [MeSH-minor] Adult. Capecitabine. Female. Fluorouracil / analogs & derivatives. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Predictive Value of Tests. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16279094.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; EC 1.3.1.2 / Dihydrouracil Dehydrogenase (NADP); EC 2.1.1.45 / Thymidylate Synthase; EC 2.4.2.4 / Thymidine Phosphorylase; U3P01618RT / Fluorouracil
  •  go-up   go-down


92. Hünerbein M, Hohenberger P, Stroszczynski C, Bartelt N, Schlag PM, Tunn PU: Resection of soft tissue sarcoma of the lower limb after evaluation of vascular invasion with intraoperative intravascular ultrasonography. Br J Surg; 2007 Feb;94(2):168-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resection of soft tissue sarcoma of the lower limb after evaluation of vascular invasion with intraoperative intravascular ultrasonography.
  • BACKGROUND: This study investigated the value of intravascular ultrasonography (IVUS) in the intraoperative assessment of vascular invasion of soft tissue sarcoma.
  • METHODS: In a 4-year interval, of 337 patients with soft tissue sarcoma, 20 patients with tumours of the lower limb in close relation to the neurovascular bundle underwent intraoperative IVUS (20 MHz).
  • CONCLUSION: Vascular infiltration by soft tissue sarcoma can be visualized accurately by IVUS.
  • [MeSH-major] Blood Vessels / ultrasonography. Limb Salvage. Sarcoma / surgery. Soft Tissue Neoplasms / surgery. Ultrasonography, Interventional
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Leg / surgery. Leg / ultrasonography. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness / ultrasonography. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 British Journal of Surgery Society Ltd.
  • (PMID = 17143849.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


93. Bay JO, Ray-Coquard I, Fayette J, Leyvraz S, Cherix S, Piperno-Neumann S, Chevreau C, Isambert N, Brain E, Emile G, Le Cesne A, Cioffi A, Kwiatkowski F, Coindre JM, Bui NB, Peyrade F, Penel N, Blay JY, Groupe Sarcome Français: Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer; 2006 Aug 1;119(3):706-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis.
  • Advanced soft-tissue sarcomas are usually resistant to cytotoxic agents such as doxorubicin and ifosfamide.
  • We conducted a retrospective study on 133 patients (58 males/75 females) with unresectable or metastatic soft-tissue sarcoma.
  • No difference was found between uterine soft-tissue sarcomas versus others.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Analysis of Variance. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Diarrhea / chemically induced. Drug Administration Schedule. Female. Humans. Leiomyosarcoma / drug therapy. Leiomyosarcoma / pathology. Male. Middle Aged. Nausea / chemically induced. Neutropenia / chemically induced. Retrospective Studies. Survival Analysis. Taxoids / administration & dosage. Taxoids / adverse effects. Thrombocytopenia / chemically induced. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Wiley-Liss, Inc.
  • [ErratumIn] Int J Cancer. 2007 Jan 15;120(2):450. Penel, Nicolas [added]
  • (PMID = 16496406.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


94. Saito A, Sawaizumi M, Imai T, Matsumoto S: Reconstruction following resection of soft-tissue sarcomas at the ankle region in seven patients. J Plast Reconstr Aesthet Surg; 2010 Oct;63(10):1712-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reconstruction following resection of soft-tissue sarcomas at the ankle region in seven patients.
  • The defects following soft-tissue or bone malignancies resection tend to be wide and composite at the region of ankle, and reconstruction of the defects is a difficult task.
  • All of the patients underwent free tissue transfer, and the selected methods are different for each case.
  • We consider it important to select reconstructive options based on the size and volume of the defects and tissue deficiency; and free tissue transfer is useful for the reconstruction of the wide and composite defects at the ankle region.
  • [MeSH-major] Ankle / surgery. Reconstructive Surgical Procedures / methods. Sarcoma / surgery. Surgical Flaps
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy. Bone Neoplasms / pathology. Bone Neoplasms / surgery. Child. Female. Humans. Male. Middle Aged. Osteosarcoma / pathology. Osteosarcoma / surgery. Recovery of Function. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 19879204.001).
  • [ISSN] 1878-0539
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


95. Sleijfer S, Ouali M, van Glabbeke M, Krarup-Hansen A, Rodenhuis S, Le Cesne A, Hogendoorn PC, Verweij J, Blay JY: Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer; 2010 Jan;46(1):72-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
  • BACKGROUND: Adult patients with advanced soft tissue sarcomas (STS) are generally treated similarly, regardless of great differences between STS subtypes, disease presentation and patients' characteristics.
  • METHODS: A retrospective, exploratory analysis was performed on data from 1337 advanced STS patients who received first-line ifosfamide-containing chemotherapy.
  • RESULTS: Independent favourable prognostic factors for overall survival (OS) were good performance status, female gender, low histological grade, extremity primary tumour site and locally advanced disease; for progression-free survival (PFS), the combination of doxorubicin and ifosfamide, locally advanced disease, and tumour entity with a lower risk to progress for synovial sarcoma patients compared to leiomyosarcoma.
  • For response, independent favourable prognostic factors were doxorubicin combined with ifosfamide, higher histological grade, and histology with synovial sarcoma patients having the highest chance to respond.
  • CONCLUSION: In this study, we established an independent set of prognostic and predictive factors for outcome to ifosfamide-based chemotherapy in advanced STS patients.
  • This study provides important information for the interpretation and design of clinical trials for specific STS entities and may contribute to further treatment individualisation of advanced STS patients.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Ifosfamide / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy


96. Berezhnaya NM, Vinnichuk UD, Konovalenko VF, Vorobjova LI, Belova OB, Proskurnia LA: The sensitivity of chemioresistant human tumor explants to lysis by activated and nonactivated autological lymphocytes: a pilot study. Exp Oncol; 2005 Dec;27(4):303-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: The comparative study of antitumor action of peripheral blood lymphocytes (PBL) and lymphokin-activated killer cells (LAK) on autologous cell of chemoresistant and chemosensitive human soft tissue sarcomas and tumors of epithelial origin.
  • MATERIALS AND METHODS: Tumor explants (15 samples of soft tissue sarcomas, 10 samples of cervical and ovarian carcinomas) were cultivated with autologous lymphocytes in double diffusion chambers.
  • RESULTS: The results have shown that in the patients with the resistant soft tissue sarcomas and carcinomas LAK possess more pronounced antitumor action, than non-activated lymphocytes, whilst PBL possess higher antitumor action on sensitive epithelial tumors than that on soft tissue sarcoma.
  • [MeSH-major] Drug Resistance, Neoplasm / immunology. Killer Cells, Lymphokine-Activated / immunology. Lymphocytes / immunology. Neoplasms, Glandular and Epithelial / immunology. Sarcoma / immunology. T-Lymphocyte Subsets / immunology
  • [MeSH-minor] Adult. Cells, Cultured. Cytotoxicity, Immunologic. Female. Humans. Lymphocyte Activation / immunology. Middle Aged. Ovarian Neoplasms / immunology. Pilot Projects. Soft Tissue Neoplasms / immunology. Uterine Cervical Neoplasms / immunology

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16404351.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ukraine
  •  go-up   go-down


97. Engelhardt TO, Jeschke J, Piza-Katzer H: [About the self-reported quality of life after amputation of the hand in patients with upper extremity tumors]. Handchir Mikrochir Plast Chir; 2008 Feb;40(1):23-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE/BACKGROUND: Amputation proximal to the wrist may be oncologically dictated in cases of upper extremity soft tissue sarcoma and aggressive fibromatosis.
  • PATIENTS/METHODS: Between 1999 and 2007, 14 patients (6 females/8 males; average age: 25 years) were operated because of a soft tissue sarcoma (n = 11) or aggressive fibromatosis (n = 3).
  • [MeSH-major] Amputation. Amputees / psychology. Arm. Artificial Limbs. Fibromatosis, Aggressive / surgery. Hand / surgery. Quality of Life. Sarcoma / surgery
  • [MeSH-minor] Activities of Daily Living. Adult. Child. Disability Evaluation. Female. Humans. Infant. Male. Middle Aged. Patient Satisfaction. Reoperation. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Artificial Limbs.
  • MedlinePlus Health Information. consumer health - Limb Loss.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18322896.001).
  • [ISSN] 0722-1819
  • [Journal-full-title] Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft für Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft für Mikrochirurgie der Peripheren Nerven und Gefässe : Organ der Vereinigung der Deutschen Plastischen Chirurgen
  • [ISO-abbreviation] Handchir Mikrochir Plast Chir
  • [Language] ger
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


98. Kawaguchi K, Oda Y, Saito T, Takahira T, Yamamoto H, Tamiya S, Iwamoto Y, Tsuneyoshi M: Genetic and epigenetic alterations of the PTEN gene in soft tissue sarcomas. Hum Pathol; 2005 Apr;36(4):357-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic and epigenetic alterations of the PTEN gene in soft tissue sarcomas.
  • To investigate the potential role and the alteration of the PTEN gene in soft tissue sarcomas (STSs), we searched for homozygous deletion and promoter hypermethylation in a series of 48 STSs that was composed of malignant fibrous histiocytoma, leiomyosarcoma, malignant peripheral nerve sheath tumor, including 2 cases with a mutation that we previously reported; differential polymerase chain reaction and methylation-specific polymerase chain reaction, respectively, were used for the analyses.
  • Decreased expression of PTEN protein was recognized in 11 (29%) of 38 STS cases.
  • Furthermore, decreased expression of the PTEN gene showed a statistically significant correlation with high MIB-1 labeling index in 38 STS cases examined ( P = .0441).
  • In conclusion, promoter methylation and homozygous deletion of the PTEN gene were found to be relatively rare events in cases of STS, as is mutation of the gene.
  • Furthermore, although a further detailed analysis of a larger number of cases is still necessary, the present results suggest that PTEN expression may be a useful indicator of cell proliferation in patients with STS.
  • [MeSH-major] Membrane Proteins / genetics. Phosphoric Monoester Hydrolases / genetics. Protein Tyrosine Phosphatases / genetics. Sarcoma / genetics. Soft Tissue Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Proliferation. Child. Child, Preschool. DNA Methylation. Female. Gene Deletion. Humans. Infant. Male. Middle Aged. Mutation. PTEN Phosphohydrolase. Promoter Regions, Genetic

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15891996.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Proteins; EC 3.1.3.- / Phosphoric Monoester Hydrolases; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.1.3.48 / TPTE protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


99. Anderson ME, Hornicek FJ, Gebhardt MC, Raskin KA, Mankin HJ: Alveolar soft part sarcoma: a rare and enigmatic entity. Clin Orthop Relat Res; 2005 Sep;438:144-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alveolar soft part sarcoma: a rare and enigmatic entity.
  • Alveolar soft part sarcoma is a rare malignant tumor with unusual clinical behavior.
  • Treatment of alveolar soft part sarcoma has been difficult to evaluate because of the small numbers of cases seen, but it seemed that although treatment of the primary tumor in alveolar soft part sarcoma often is successful, treatment of metastatic tumors is unsuccessful.
  • A review of outcome after treatment of primary and metastatic disease in the 15 patients in our database with alveolar soft part sarcoma was done in order to evaluate this issue.
  • New approaches to treatment of metastatic alveolar soft part sarcoma must be investigated and applied.
  • [MeSH-major] Neoplasm Metastasis / pathology. Sarcoma, Alveolar Soft Part / secondary. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Male. Mesna / administration & dosage. Neoplasm Staging. Survival Rate

  • Genetic Alliance. consumer health - Alveolar Soft Part Sarcoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16131883.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; NR7O1405Q9 / Mesna; UM20QQM95Y / Ifosfamide; MAID protocol
  •  go-up   go-down


100. Manoso MW, Frassica DA, Deune EG, Frassica FJ: Outcomes of re-excision after unplanned excisions of soft-tissue sarcomas. J Surg Oncol; 2005 Sep 1;91(3):153-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of re-excision after unplanned excisions of soft-tissue sarcomas.
  • BACKGROUND AND OBJECTIVES: Unplanned excisions of soft-tissue sarcomas of the extremities occur commonly.
  • Our goal was to evaluate the presence of residual disease, the treatment outcomes as they relate to local and distant recurrence and 5-year survival, and the limb functional outcomes in patients with unplanned sarcoma excision who were treated with re-excision and adjuvant therapy.
  • METHODS: Between 1993 and 1999, 42 patients presented to our institution after unplanned excision of soft-tissue sarcomas.
  • Univariate analysis showed that stage-III disease (American Joint Committee on Cancer classification of soft-tissue sarcomas), lesions below the fascia, a histologic high-grade, and the development of organ metastasis were statistically significant factors for mortality.
  • [MeSH-major] Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Baltimore / epidemiology. Combined Modality Therapy. Female. Humans. Logistic Models. Male. Middle Aged. Multivariate Analysis. Proportional Hazards Models. Reoperation. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16118773.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement